Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
10/2009 | Recent  |  14: Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions October categorized by USPTO classification 10/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
10/30/2009 > patent applications in patent subcategories. categorized by USPTO classification
  
10/23/2009 > patent applications in patent subcategories. categorized by USPTO classification
  
10/15/2009 > patent applications in patent subcategories. categorized by USPTO classification

20090258815 - Antiviral peptide and antiviral agent: Disclosed is an antiviral agent comprising a non-naturally occurring, artificially synthesized peptide as the main ingredient. The antiviral agent comprises an antiviral peptide, wherein the antiviral peptide has at least one unit of an amino acid sequence constituted by at least five contiguous amino acid residues (which is known as... Agent: Turocy & Watson, LLP

20090258814 - Method for treating a synucleinopathy: The present invention relates to methods for restoring fast axonal transport in a cell which expresses a pathological synuclein protein and for treating a synucleinopathy using a Protein Kinase C mu or Src-Family Tyrosine Kinase inhibitor.... Agent: Jane Massey Licata Licata & Tyrrell P.C.

20090258816 - Use of gpcr agonists to delay progression of diabetes: The present invention is directed to the use of G-protein coupled receptor agonists for the treatment of beta-cell degeneration.... Agent: Osi Pharmaceuticals, Inc.

20090258817 - Arylsulfanyl compounds and compositions for delivering active agents: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are also provided.... Agent: Emisphere Technologies, Inc

20090258818 - Compositions for the treatment of diabetes: A supramolecular insulin assembly and supramolecular exendin-4 assembly, which is useful as a protein therapeutic agent for the treatment of metabolic disorders particularly diabetes. The supramolecular assemblies disclosed in the present invention consists of insoluble and aggregated oligomers the protein. The invention also provides pharmaceutical compositions comprising the supramolecular assembly.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090258820 - Echinocandin/carbohydrate complexes: A complex of an echinocandin compound with a carbohydrate is described having improved thermal stability and water solubility. A process for making the echinocandin/carbohydrate complex is also described as well as the use of the complex in pharmaceutical formulations and treatments of fungal infections.... Agent: Pfizer Inc Mary J Hosley

20090258819 - Reagents and methods for smooth muscle therapies: The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090258822 - Diagnosis and treatment of age-related macular degeneration: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.... Agent: Townsend And Townsend And Crew, LLP

20090258821 - Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window: Methods and uses are provided for a pharmaceutical composition with an erythropoietin or a tissue protective cytokine for protecting or restoring function to a responsive cell, tissue, organ or body part function or viability in mammals when administered outside of the therapeutic window of previously approved therapeutics.... Agent: Jones Day

20090258824 - Amyloid beta receptor and uses thereof: The present invention relates to the identification that soluble assemblies of amyloid β function as a NMDA receptor antagonist. The present invention also provides methods and compositions for the detection and treatment of neurodegenerative and cognitive disorders and screening methods to identify agents that modulate the antagonistic effect of soluble... Agent: Mueting, Raasch & Gebhardt, P.A.

20090258823 - Composition and methods for the prevention and treatment of gastrointestinal infections: Methods for the prevention and treatment of gastrointestinal infections are described. Surfactant-associated protein-A (SP-A) or SP-D or an active fragment or derivative thereof is administered to mammals at risk of a gastrointestinal infection. Oral compositions of SP-A and/or SP-D are disclosed. Also disclosed is a method to prevent or treat... Agent: Foley & Lardner LLP

20090258832 - Cytokines and cytokine receptors with reduced immunocencity: The present invention provides methods for the identification of CD4+ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no longer capable of initiating the CD4+ T-cell response. In some... Agent: Kamrin T. Macknight Genencor International, Inc.

20090258830 - Diagnostic and therapeutic uses of gelsolin in renal failure: The invention is directed, in part, to the use of gelsolin to diagnose, monitor, and treat subjects with renal failure (e.g., chronic renal failure subjects on dialysis).... Agent: Wolf Greenfield & Sacks, P.C.

20090258833 - Fortified liquid protein compositions and methods of making same: A fortified liquid protein composition and method includes hydrolyzed collagen and a desired abundance of sulfur containing amino acids and optionally taurine.... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090258825 - Hopm1 mediated disease resistance to pseudomonas syringae in arabidopsis: The present invention relates to compositions and methods for enhancing plant defenses against pathogens. More particularly, the invention relates to enhancing plant immunity against bacterial pathogens, wherein HopM11-300 mediated protection is enhanced, such as increased protection to Pseudomonas syringae pv. tomato DC3000 HopM1 and/or there is an increase in activity... Agent: Medlen & Carroll, LLP

20090258828 - Investigation of mucosa dryness conditions: The present invention relates to diagnosis and/or treatment of medical conditions. The present invention relates to new method of diagnosing dry mucosa condition in a subject. The condition may be dry eye. The present invention also provides a method to monitor the efficacy of a treatment of a dry mucosa... Agent: Heslin Rothenberg Farley & Mesiti PC

20090258829 - New formulation for increasing bioavailability of neurturin: The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090258826 - Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use: This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides are shown to lower blood glucose in vivo more than controls upon glucose challenge. The polypeptides of this invention are also stable in formulation and have long half-lives. The peptides of... Agent: Edwards Angell Palmer & Dodge LLP

20090258827 - Transcription factor modulator: The present invention relates to novel agents that are useful for modulating transcription factor activity. In particular, the present invention relates to A transcription factor modulator comprising (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof or pharmaceutical composition thereof; or (ii) a compound or composition... Agent: K&l Gates LLP

20090258831 - Treatment using neublastin polypeptides: The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.... Agent: Fish & Richardson

20090258834 - Plasma protein-binding ligands: The invention provides an isolated or purified peptide that binds at least one plasma protein. In one embodiment, the isolated or purified peptide binds to fibrinogen, comprises no more than 10 amino acids, and comprises an amino acid sequence Xaa1-Xaa2-Xaa3-Xaa4-Xaa5, an amino acid sequence Gly-Xaa6-Arg-Xaa7, or an amino acid sequence... Agent: Drinker Biddle & Reath (dc)

20090258835 - Compounds that stimulate glucose utilization and methods of use: wherein W, Cyc, p, Y, X, Z, R, R1, R2, R3, R4, I, m and n are as defined for Formula (I) herein. The invention also relates to pharmaceutical compositions comprising compounds capable of stimulation of glucose oxidation, methods for increasing glucose oxidation rates in myocardial cells, and methods of... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090258923 - Carrier composition for nucleic acid transport: e

20090258929 - Compositions and methods for modulating mtor signaling: The present invention relates to the use of antagonists of the mTOR signaling pathway and its constituent members (e.g., antagonists of MAPKAP) for the treatment, amelioration, and diagnosis of PI3K/AKT/mTOR-related disorders, e.g., cancers. The present invention also relates to methods of using modulators of mTOR (e.g., modulators of MAPKAP) for... Agent: Novartis Corporate Intellectual Property

20090258927 - Method for the modulation of function of transcription factors: There is provided a method of modulating the function of transcription factor by administering an effective amount of an oligonucleotide containing optimal nucleotide binding sites for the transcription factor. A therapeutic agent having an effective amount of an oligonucleotide for modulating function of transcription factors and a pharmaceutically acceptable carrier... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090258926 - Methods and compositions for delivering sirna into mammalian cells: Complex comprising a peptide carrier of SEQ ID NO:1 GALFLGFLGAAGSTMGAWSQPKR1KRKVR2 and an appropriate siRNA, wherein R1 represents any amino acid residue and more preferably K or S, R2 is null or represents one of the following groups: cysteamide, cysteine, thiol, amide, linear or ramified C1-C6 alkyl optionally substituted, primary or... Agent: Morgan Lewis & Bockius LLP

20090258928 - Methods and compositions for diagnosing and modulating human papillomavirus (hpv): The present invention concerns methods and compositions for treating a patient having, suspected of having, or at risk of obtaining a HPV infection.... Agent: Fullbright & Jaworski L.L.P.

20090258924 - Methods, compositions and drug delivery systems for intraocular delivery of sirna molecules: Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.... Agent: Allergan, Inc.

20090258925 - Natural antisense and non-coding rna transcripts as drug targets: Small interfering RNA (siRNA) knock down antisense transcripts, and regulate the expression of their sense partners. This regulation can either be discordant (antisense knockdown results in sense transcript elevation) or concordant (antisense knockdown results in concomitant sense transcript reduction).... Agent: Wilson Sonsini Goodrich & Rosati

20090258931 - Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry: The present invention relates to novel chimeric oligomeric compounds having a plurality of alternating regions having either RNA like having northern or 3′-endo conformational geometry (3′-endo regions) or DNA like having southern or C2′-endo/O4′-endo conformational geometry. The oligomeric compounds of the present invention have shown reduction in mRNA levels in... Agent: Woodcock Washburn LLP

20090258934 - Compositions and methods for inhibiting expression of nav1.8 gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The... Agent: Alnylam/fenwick

20090258930 - Double stranded rna structures and constructs, and methods for generating and using the same: The present invention relates to novel double stranded RNA (dsRNA) structures and dsRNA expression constructs, methods for generating them, and methods of utilizing them for silencing genes. Desirably, these methods specifically inhibit the expression of one or more target genes in a cell or animal (e.g., a mammal such as... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090258935 - Hybrid adeno-retroviral vector for the transfection of cells: An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic... Agent: Klarquist Sparkman, LLP

20090258932 - Lyophilized dna formulations for enhanced expression of plasmid dna: The present invention provides for a method of treating or preventing ischemic or liver disease in a subject by administering a composition reconstituted from a lyophilized hepatocyte growth factor (HGF) DNA formulation, where the DNA formulation comprises an HGF plasmid DNA, salt and a carbohydrate. The invention further provides for... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090258933 - Oligonucleotides-transferring preparations: Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided.... Agent: Birch Stewart Kolasch & Birch

20090258836 - Effective delivery of cross-species a3 adenosine-receptor antagonists to reduce intraocular pressure: Provided are methods for reducing intraocular pressure in an individual having an ocular disorder causing elevated intraocular pressure, such as glaucoma. The method comprises administering to the individual an effective intraocular pressure-reducing amount of a pharmaceutical composition comprising an A3 subtype adenosine receptor (A3AR) antagonist, including dihydropyridine, pyridine, pyridinium salt... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090258837 - Analogous compounds of 6-thioguanosine triphosphate, their use in medical fields and processes for their preparation: The invention relates to analogous compounds of 6-thioguanosine triphosphate of general formula (I). A compound of the general formula (I); wherein the dashed bond in the sugar moiety can be either single or double and wherein R1, R2, R3, R4 or R5, equal or different between each other, have general... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090258838 - Gel formulation: The present invention relates to a sterile gel formulation comprising calcium gluconate. It also relates to a sterilisable gel formulation comprising calcium gluconate, which is stable under gamma-radiation sterilisation conditions, and also to the use of these formulations in, for example, treating burns caused by exposure of a human or... Agent: Barlow, Josephs & Holmes, Ltd.

20090258839 - Compositions comprising chitosan suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome: The present invention relates to compositions comprising chitosan, in the form of drugs or food supplements, suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome. Also described is their preparation. More generally, the invention concerns the use of chitosan for comprehensive therapeutic treatment or comprehensive prevention of... Agent: Knobbe Martens Olson & Bear LLP

20090258840 - Method and compositions for treating hematological malignancies: A compound of formula (1), and/or its salts, tautomers or solvates is used to treat hematological malignancies. In an embodiment, an organic acid salt of compound 1 is provided for general use in treatment of neoplasms, and in a further embodiment the salt is stabilized with carbohydrate.... Agent: Gilead Sciences Inc

20090258841 - Compositions and methods for skin care: Compositions and methods are for disclosed for treating a skin condition that results from reactive oxygen species production in skin of a subject, including applying a topical formulation that contains a lipophilic cation-mitochondrially targeted antioxidant compound and that delivers a therapeutically effective amount of the antioxidant compound to skin fibroblasts... Agent: Seed Intellectual Property Law Group PLLC

20090258842 - 7-phenyl-substituted tetracycline compounds: 7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090258843 - Compositions containing antiviral compounds and methods of using the same: The present invention is directed to compositions and methods for the treatment of various diseases, pathological disorders, and medical conditions such as viral infections and cancer. The compositions include (A) an antiviral compound or a pharmaceutically acceptable salt thereof; and (B) an agent selected from the group consisting of a... Agent: Mallinckrodt Inc.

20090258844 - Compositions and methods for the treatment of disorders of the central and peripheral nervous systems: The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for... Agent: Hunton & Williams LLP Intellectual Property Department

20090258845 - Combination dosage forms and therapies for supporting bone health: Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090258847 - Cholanic acid amides: 4-(3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-pentanoic acid amides wherein the nitrogen of the amide group is substituted by a sulfonylaminocarbonyl-(C1-4)-alkyl group; and the use of such compounds as pharmaceuticals.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090258846 - Eyebrow re-growth stimulator for re-growth of lost eyebrows: A chemical composition and method of an eyebrow re-growth stimulator for women who has lost there eyebrows due to dease and treatments. The lose of harmons and other causes such as in ageing women population. The eyebrow regrowth composition methods of topical treatment in an effective amount of the treatment... Agent: Linda Sue Apple

20090258848 - Biomarkers for inflammatory bowel disease: The present invention relates to methods of determining inflammatory bowel disease status in a subject. The invention further relates to kits for determining inflammatory bowel disease status in a subject. The invention further related to methods of identifying biomarker for determining inflammatory bowel disease status in a subject.... Agent: Edwards Angell Palmer & Dodge LLP

20090258849 - Nitrooxy derivatives of glucocorticoids: The invention relates to new steroids nitrooxyderivatives, to topical pharmaceutical formulations thereof, and their use for treating skin or mucosal membrane diseases or disorders. These new steroids nitrooxyderivatives have an improved pharmacological activity and enhanced local tolerability.... Agent: Arent Fox LLP

20090258850 - Stabilized therapeutic compositions and formulations: The invention relates to pharmaceutically acceptable formulations comprising an active pharmaceutical ingredient such as androst-5-ene-3β,17β-diol, androst-5-ene-3β,7β,17β-triol or derivatives of either of these compounds and an air oxidizable excipient that have been stabilized with respect to efficacy. Use of the efficacy-stabilized formulations to treat a number of conditions or symptoms thereof,... Agent: Hollis-eden Pharmaceuticals, Inc.

20090258851 - Diaryl substituted alkanes: e

20090258855 - Bicyclic triazoles as protein kinase modulators: The present disclosure provides bicyclic triazole protein kinase modulators and methods of using these compounds to treat diseases mediated by kinase activity.... Agent: Eli Lilly & Company

20090258852 - Inhibitors of checkpoint kinases: The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.... Agent: Merck And Co., Inc

20090258853 - Somatostatin agonists: This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this... Agent: Merck And Co., Inc

20090258854 - Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene a4 hydrolase: Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.... Agent: Philip S. Johnson Johnson & Johnson

20090258856 - Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions: i

20090258857 - Chemical compounds: The present invention encompasses compounds of general formula (1) wherein R1, M1, L1 and Q are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090258858 - Muscarinic acetylcholine receptor antagonists: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090258859 - Metronidazole cocrystals and imipramine cocrystals: Cocrystals of metronidazole are described herein. Such cocrystals are a cocrystal of metronidazole with gentisic acid and a cocrystal of metronidazole with gallic acid. Cocrystals of imipramine hydrochloride are also described. Such cocrystals are a cocrystal of imipramine hydrochloride with (+)-camphoric acid, a cocrystal of imipramine hydrochloride with fumaric acid,... Agent: Nixon Peabody, LLP

20090258860 - Xanthine derivatives for the treatment of vascular depression: Methods and compositions are provided for treating vascular depression. The methods involve administering to a subject in need thereof a xanthine derivative in a therapeutically effective amount to treat vascular depression, particularly the xanthine derivatives pentoxifylline or propentofylline. The methods may further include administration of an additional therapeutic agent in... Agent: Alston & Bird LLP

20090258861 - Tetrahydronaphthyridine derivatives: t

20090258862 - Niacin receptor agonists, compositions containing such compounds and methods of treatment: Compounds of the formula (I): as well as pharmaceutically acceptable salts and solvates are disclosed. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, VLDL and triglycerides, and raising HDL levels. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20090258863 - Method for treatment of amyotrophic lateral sclerosis using talampanel: A method of treating a human patient afflicted with amyotrophic lateral sclerosis (ALS) comprising periodically administering to the human patient for a therapeutically effective duration a pharmaceutical composition comprising an amount of talampanel therapeutically effective to provide a benefit to the human patient, thereby treating the human patient.... Agent: Cooper & Dunham, LLP

20090258865 - Administration of benzodiazepine compositions: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.... Agent: Wilson, Sonsini, Goodrich & Rosati

20090258866 - Cgrp receptor antagonists: The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury,... Agent: Louis J. Wille Bristol-myers Squibb Company

20090258864 - Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases: n, m, Y, R1, R2, R3, R4 and R5 are disclosed herein, as isolated stereoisomers or mixtures thereof, or as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising the compounds of formula (I); and methods of using the compounds and the pharmaceutical compositions in treating diseases or conditions associated with JAK2... Agent: Seed Intellectual Property Law Group PLLC

20090258867 - Pyrazolo[1,5-a] pyrimidine compounds as cb1 receptor antagonist: The present invention provides a pyrazolo[1,5-a]pyrimidine compound, having CB1 receptor-antagonizing activity, of the following formula [I]: in which R1 and R2 are the same or different and each an optionally substituted aryl group etc, R0 is hydrogen atom, an alkyl group etc, E is a group of the formula: —C(═O)—... Agent: Birch Stewart Kolasch & Birch

20090258868 - Heterocyclic aspartyl protease inhibitors: e

20090258869 - Methods and compounds for treatment or prevention of substance-related disorders: The present disclosure provides methods of treating or preventing a substance-related disorder using Hsp90 inhibitors, Hsp90 modulators, tyrosine hydroxylase modulators, and modulators that reduce the interaction between Hsp90 and tyrosine hydroxylase.... Agent: Jones Day

20090258870 - Novel ansamitocin derivatives: Provided are among other things ansamitocin derivatives, pharmaceutical compositions comprising these novel ansamitocin derivatives, methods for the production of the ansamitocin derivatives and their use for the treatment of cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20090258871 - Aza-substituted spiro derivatives: [wherein X, Y, Z and W each independently represent a methine group or a nitrogen atom, provided that a case where all of X, Y, Z and W are methine group; A represents —O— or the like, B represents —C(O)— or the like, D represent —(CH2)m2-, —O— or the like,... Agent: Merck And Co., Inc

20090258872 - Use of aryl-substituted polycyclic amines as medicaments: h

20090258873 - Novel tetrahydropyridothiophenes: Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.... Agent: Millen, White, Zelano & Branigan, P.C.

20090258874 - Pyrazolo-heteroaryl compounds: m

20090258875 - Fungicide hydroximoyl-tetrazole derivatives: The present invention relates to hydroximoyl-tetrazole derivatives of formula (I) wherein T represent a tetrazolyl substituents, A represents a carbo- or heterocycle, L1 and L2 represent various linking groups and Q represents a carbocycle, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide... Agent: Ostrolenk Faber Gerb & Soffen

20090258876 - Novel indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient: Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have... Agent: Lucas & Mercanti, LLP

20090258877 - Triazolotriazines and triazolopyrazines and their use: The invention relates to substituted triazolotriazines and triazolopyrazines and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular haematologic disorders, preferably of leukopenias and neutropenias.... Agent: Nixon Peabody LLP

20090258878 - Triazine derivative compound and composition for treating cancer containing them: The present invention relates to a Triazine derivative compound, pharmaceutically acceptable salt thereof and a pharmaceutical composition containing them. Compound or composition of the present invention is useful for cancer treatment, and especially has superior effect in breast cancer treatment.... Agent: Robert E. Bushnell & Law Firm

20090258881 - Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament: e

20090258879 - Method for treating cancer, rheumatoid arthritis and other medical diseases by utilizing modified virus virions to insert medications into targeted cells: A safer, more effective treatment of many medical diseases may be approached by a method utilizing modified viruses as vehicles to transport medically therapeutic drug molecules to specific cells in the body with the intent to have the drug exert an effect only on those cells to which the modified... Agent: Lane B. Scheiber

20090258880 - Substituted tetrahydropyrrolopyrazine compounds and the use thereof in pharmaceutical compositions: s

20090258882 - 2,4-substituted quinazolines as lipid kinase inhibitors:

20090258883 - 1h-indole-pyridinecarboxamide and 1h-indole-piperidinecarboxamide compounds:

20090258884 - Substituted amides: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20090258885 - Diphenylmethane derivatives as inhibitors of leukotriene biosynthesis: The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents.... Agent: Merck And Co., Inc

20090258886 - Heteroalkyl linked pyrimidine derivatives: The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to heteroalkyl linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be... Agent: Connolly Bove Lodge & Hutz LLP

20090258887 - Novel carboxylic acid derivatives: The present invention is concerned with novel arylalkyl carboxylic acid derivatives, more specifically, with acylates of arylalkyl carboxylic acids with naturally occurring, non-toxic hydroxy, sulfhydryl, amino or imino compounds, and to compositions containing them. The compositions are preferably cosmetic preparations.... Agent: Nixon & Vanderhye, PC

20090258888 - Pyrimidine derivatives: This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20090258889 - Pesticidal compositions: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.... Agent: Patent Docket Department Armstrong Teasdale LLP

20090258890 - Topoisomerase-targeting agents: the bond represented by is a single bond or a double bond, and R1-R5, X, and Y have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I or II, processes for preparing compounds... Agent: Viksnins Harris & Padys Pllp

20090258891 - Macrocyclic compounds as antiviral agents: The present invention relates to macrocyclic compounds of formula (I): wherein W, n, R1, Ra, Rb, R3, R4, M, Z, ring A and ring B are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C... Agent: Merck And Co., Inc

20090258892 - Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof: Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present... Agent: Fish & Richardson P.C.

20090258893 - Fused quinoline derivative and use thereof: s

20090258894 - Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is... Agent: Merck And Co., Inc

20090258895 - Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus): The present invention relates to a pharmaceutical formulation and process for preparing the same comprising an oral dosage formulation, such as a capsule formulation, of a macrolide compound, such as tacrolimus, wherein the capsule formulation contains both a solid dispersion of the macrolide along with a non-dispersed form of the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090258896 - Composition comprising at least one higher aliphatic alcohol and an extract of griffonia simplicifolia: Novel compositions comprising a combination of at least one higher primary aliphatic alcohol preferably selected from those having 18 to 40 carbon atoms or mixtures thereof, at least one source of 5-hydroxytryptophan (5-HTP) optionally additionally comprising a source of caffeine and/or catechin-polyphenol and/or epigallocatechin gallate as active agents, either alone... Agent: Ladas & Parry LLP

20090258897 - Substituted benzimidazoles: Disclosed herein are substituted benzimidazole-based proton pump modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20090258898 - Amides of acetic and propionic acids: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.... Agent: Edwards Angell Palmer & Dodge LLP

20090258899 - Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof: e

20090258900 - Amide derivative: A is a cycloalkyl group, an aryl group or a heteroaryl group; X is a nitrogen atom or CR17; Y is —NRa—, —(CRbRb′)m-, and the like; m is 0 to 4; and R1 to R17 may be the same or different and each is a hydrogen atom, a halogen atom,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20090258901 - Ligands for monoamine receptors and transporters, and methods of use thereof: One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment... Agent: Jones Day

20090258902 - Biphenyl-pyrazolecarboxamide compounds: The present invention relates to biphenyl-pyrazole compounds and in particular biphenyl-pyrazolecarboxamides. The invention further provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by antagonism or inverse agonism of the CB1 receptor, such as obesity, smoking... Agent: Edwards Angell Palmer & Dodge LLP

20090258903 - Aminoethane sulfonamide orexin receptor antagonists: The present invention is directed to aminoethane sulfonamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20090258904 - Epithiolone analogues: Epothilone analogues include a molecular scaffold which holds at least one segment of epothilone in a predetermined orientation and which rigidities a region between the macrolactone ring and the aromatic side-chain.... Agent: Macmillan Sobanski & Todd, LLC

20090258905 - Phosphodiesterase-4 inhibitors belonging to the tertiary amine class: o

20090258906 - Cxcr2 antagonists: in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090258907 - Compounds useful as inhibitors of rock kinases:

20090258908 - Crystalline s-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same: This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.... Agent: Sughrue Mion, PLLC

20090258909 - Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms): The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.... Agent: Philip S. Johnson Johnson & Johnson

20090258910 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, lck, SAPK2α, p38, TGFβ,... Agent: Genomics Institute Of The Novartis Research Foundation

20090258911 - Composition and method for treating fibrotic diseases: The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones have enhanced anti-fibrotic activities than 5-methyl-1-(non-substituted phenyl)-2(1H)-pyridones. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone. Accordingly, there are provided compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat or prevent fibrosis... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090258912 - N-(1-alkyl-2-phenylethyl)-carboxamide derivatives and use thereof as fungicides: e

20090258913 - Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1: Triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM.... Agent: Merck And Co., Inc

20090258914 - Inhibitor of anti-apoptotic proteins: A compound having the structure A is described as well as the use of such compounds to inhibit at least one BCL-2 protein family member.... Agent: Dla Piper LLP (us)

20090258915 - Ribonucleotide reductase inhibitors and methods of use: Provided herein are novel compounds that inhibit ribonucleotide reductase (RR) by binding to RRM2 and interfering with the activity of the RRM1/RRM2 holoenzyme. These inhibitors may be used to inhibit RR activity and to treat various conditions associated with RRM2 expression, such as for example certain cancer types, mitochondrial diseases,... Agent: Perkins Coie LLP

20090258916 - Low-melting biocidal formulation: A low-melting biocidal composition comprising 4,5-dichloro-2-octyl-3(2H)-isothiazolone, 3-iodopropargyl-N-butyl carbamate and at least one C1-C4 alkyl 4-hydroxybenzoate. The composition is stable with regard to agglomeration and crystallization at room temperature.... Agent: Rohm And Haas Company Patent Department

20090258917 - Benzoxazoles useful in the treatment of inflammation: wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and... Agent: Morgan Lewis & Bockius LLP

20090258918 - Ep4 receptor agonist, compositions and methods thereof: This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient.... Agent: Merck And Co., Inc

20090258919 - Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / or congestive heart failure: The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090258921 - Indole derivatives: e

20090258920 - Injectable formulation of antibiotic and solution for intravenous administration thereof: A pharmaceutical composition for injection comprising a depsipeptide antibiotic, WAP-8294A2, as an active ingredient, which is stable and contains WAP-8294A2 in high concentrations is provided. This composition comprises WAP-8294A2 of the following structural formula (1) as an active ingredient and is characterized in that 2-hydroxypropyl-β-cyclodextrin or β-cyclodextrin is contained as... Agent: Buchanan, Ingersoll & Rooney PC

20090258922 - Compound exhibiting pgd2 receptor antagonist: p

20090258936 - Cxcr2 inhibitors: in which R1, R2, A, B, X and Y have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090258937 - Methods for modulating tumor growth and metastasis: Methods and pharmaceutical compositions for modulating tumor growth or metastasis are provided.... Agent: Oxigene, Inc. C/o Law Offices Of Karen E. Flick

20090258938 - Administration of 6'-ethyl lepimectin, 6' -methyl lepimectin or derivatives thereof for treating dermatological disorders in humans: 6′-ethyl lepimectin, 6′-methyl lepimectin or derivatives thereof are formulated into pharmaceutical compositions useful for the treatment of dermatological conditions in humans, in particular rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20090258940 - American cranberry extract and its use: The present invention relates to an extract derived from Vaccinium and to the process for obtaining this extract. This proanthocyanidin-rich extract can be used as a dietary or nutraceutical preparation.... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090258942 - Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases: Estrogenic compositions comprising calycosin and analogs thereof are provided. Also provided are methods of using said extracts to achieve an estrogenic effect, especially in a human, e.g. a female human. In some embodiments, the methods include treatment of climacteric symptoms. In some embodiments, the methods include treatment of estrogen receptor... Agent: Wilson, Sonsini, Goodrich & Rosati

20090258939 - Pyrone analog compositions and methods: Novel pyrone analogs are described which can enhance the effectiveness of a therapeutic agent when administered and/or reduce side effects caused by the administration of a therapeutic agent.... Agent: Wilson Sonsini Goodrich & Rosati

20090258941 - Use of fusarochromanone and its derivatives in the diagnosis and treatment of cancer and other diseases: A method of photodynamic therapy to treat diseased cells in an animal is generally provided. According to the method, 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof is administered to the animal such that the 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an analog thereof accumulates in the diseased cells. Then, the diseased cells containing 5-amino-2,2-dimethyl-6-[3′-(R,S)amino-4′-hydroxy-butan-1-one]-2,3-dihydro-4H-1-benzopyran-4-one or an... Agent: Dority & Manning, P.A.

20090258943 - Hybrid strategies for reducing leaching of metal biocides from biodegradable substrates: Hybrid strategies generally involve treating biodegradable substrates with preservative compositions having at least two phases in which the metal biocide is distributed among at least the two phases and via equilibrium reactions moves between the two phases. Both phases are caused to contact the substrate in a manner so that... Agent: The Dow Chemical Company Kagan Binder, PLLC

20090258944 - Method for the manufacture of therapeutic compounds and compositions, compounds and compositions produced therewith, and their use: Organic nitrites can be produced from a compound which is a mono/polyhydric alcohol or an aldehyde- or ketone-derivate thereof after de-aeration of the same, using NO gas, and stored in an environment saturated with gaseous NO. Organic nitrites produced according to the invention exhibit less impurities and improved storage stability... Agent: Morrison & Foerster LLP

20090258945 - Lipoxin compounds and their use in treating cell proliferative disorders: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20090258946 - Electrostatically charged nasal application multipurpose products and method: A family of products designed to ameliorate sinusitis and allergic rhinitis, produced by combining certain chemical substances with existing products, thereby producing a synergistic effect and relief. The chemical substances create an electrostatically charged field around the nose and prevent allergens or pollutants from entering the nostrils to cause a... Agent: Stanley H. Kremen

20090258947 - Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof: Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions... Agent: Ladas & Parry LLP

20090258948 - Pharmaceutical salts: The invention relates to pharmaceutical salts comprised of a pharmaceutical active substance and of at least one sugar substitute, to medicaments containing these salts, and to the use of these salts for producing medicaments.... Agent: Norris, Mclaughlin & Marcus, Pa

20090258949 - Amorphous form of cinacalcet: The present invention relates to dispersions of stable amorphous cinacalcet hydrochloride in a matrix material, methods for the preparation thereof, and pharmaceutical compositions comprising said dispersions.... Agent: Manelli Denison & Selter

20090258950 - Non-toxic insecticide: A non-toxic insecticidal composition includes a base horticultural oil, an emulsifier such as potassium salts of fatty acids, cinnamaldehyde and eugenol.... Agent: Edward Yoo C/o Bennett Jones

20090258951 - Use of vanillyl alcohol for the treatment of parkinson's disease: A use of Vanillyl alcohol for treatment of Parkinson's disease is disclosed in accordance with the present invention. The Vanillyl alcohol's formula is 4-hydroxy-3-methoxy-benzyl alcohol and similitude with the human neurotransmitter dopamine. The Vanillyl alcohol has dopamine receptor stimulant and which is applied for pharmaceutical preparation of treating Parkinson's disease.... Agent: Bacon & Thomas, PLLC

20090258952 - Patch containing anti-inflammatory agent: An anti-inflammatory-containing plaster is provided. The anti-inflammatory-containing plaster may include, e.g., a styrene-isoprene-styrene block copolymer, a high molecular weight polyisobutylene, a low molecular weight polyisobutylene, a tackifier, a plasticizer, a dispersant, and an anti-inflammatory having a carboxyl group or a salt thereof. However, the anti-inflammatory-containing plaster does not contain L-menthol.... Agent: The Nath Law Group

20090258953 - Use of vinyl acetate-sulfonate copolymers as solubilizers for slightly water-solubable compounds:

20090258954 - Protective hydrocolloid for active ingredients: (Modified) rice endosperm protein is used as novel protective hydrocolloid for active ingredients, especially fat-soluble active ingredients and/or colorants. Included are compositions comprising (modified) rice endosperm protein and at least one active ingredient and to their manufacture, as well as to the (modified) rice endosperm protein itself and its manufacture.... Agent: Nixon & Vanderhye, PC

20090258955 - Intraocular irrigating solution having improved flow characteristics: Improved intraocular irrigating solutions are described comprising a cellulose derivative such as hydroxypropylmethylcellulose. In addition, certain solutions of the present invention comprise glutathione and dextrose. The solutions have enhanced viscosities that reduce the risk of damage to intraocular tissues during intraocular surgical procedures by reducing the turbulence of the solutions... Agent: Alcon

  
10/08/2009 > patent applications in patent subcategories. categorized by USPTO classification

20090253613 - Solid-fluid composition: A nanostructure comprising a core material of a nanometric size surrounded by an envelope of ordered fluid molecules is disclosed. The core material and the envelope of ordered fluid molecules are in a steady physical state. Also disclosed, a liquid composition comprising liquid and the nanostructure.... Agent: Foley And Lardner LLP Suite 500

20090253614 - Oral insulin therapies & protocol: Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired... Agent: Pearl Cohen Zedek Latzer, LLP

20090253615 - No-modified hemoglobins and uses therefor: Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090253616 - Combination therapy for the treatment of cancer: A combination comprising an aurora kinase inhibitor and an efflux transporter inhibitor wherein the aurora kinase inhibitor is a compound of formula (I) or pharmaceutically acceptable salt thereof for use in the treatment of hyperproliferative diseases such as cancer.... Agent: Astrazeneca R&d Boston

20090253626 - 50 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Foley And Lardner LLP Suite 500

20090253621 - Arabinogalactan protein having the property of absorbing fats and method for obtaining this arabinogalactan protein: The invention relates, firstly, to a method for eliminating ingested dietary fats before they are assimilated by the body, using an AGP extracted from cactus mucilage. Said AGP can be in any galenic or commercial form which is solid or dissolved in water. The invention also discloses the method of... Agent: The Marbury Law Group, PLLC

20090253617 - Diagnosis and treatment of attentional disorders: This invention features methods and compositions useful for the treatment and diagnosis of attentional disorders including attention deficit hyperactivity disorder (ADHD). Also disclosed are methods for identifying compounds useful for such therapy.... Agent: Foley & Lardner LLP

20090253623 - Gh secretagogues and uses thereof: The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime... Agent: Darby & Darby P.C.

20090253625 - Glp-1, exendin-4, peptide analogs and uses thereof: The invention relates to novel polypeptide analogues of GLP-1 and exendin-4. The polypeptide, in a preferred embodiment, is insulinotropic and long-acting. Preferably, the polypeptide's insulinotropic effect is comparable to or exceeds the effect of an equimolar amount of GLP-1 or exendin-4. The invention also relates to a method of treating... Agent: National Institute Of Health C/o Ballard Spahr Andrews & Ingersoll, LLP

20090253627 - Lactoferrin compositions and methods of wound treatment: The present invention relates to lactoferrin compositions and methods of using the compositions to treat wounds. The compositions can be administered alone or in combination with other standard wound healing therapies.... Agent: Fulbright & Jaworski, LLP

20090253620 - Methods and compositions for treating gastrointestinal radiosensititivity in a subject: A method and a related composition for treating gastrointestinal radiation sensitivity in a subject are disclosed. The method comprises administering to the subject an agent that increases either the amount of or the activity of a fasting-induced adipose factor (Fiaf) protein in a subject. The composition comprises a first agent... Agent: Polsinelli Shughart PC

20090253618 - Neuronal differentiation-inducing peptide and use thereof: A neuronal differentiation inducer comprising at least one peptide which can induce the differentiation of at least one cell into a neurocyte. The peptide is an artificially synthesized peptide comprising an amino acid sequence derived from a BC-box of at least one protein belonging to the SOCS protein family or... Agent: Turocy & Watson, LLP

20090253619 - Novel peptide involved in energy homeostasis: The expression of a mRNA encoding a putative 76 amino acid, secreted protein (“Enho1”) was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Enho1 mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Enho1... Agent: Alan F. Feeney, Esq. Biomeasure, Incorporated

20090253630 - Pegylated pth as pth receptor modulators and uses thereof: Pharmaceutical compositions and methods are provided for the treatment and prevention of bone loss diseases including osteoporosis in a mammal.... Agent: Eli Lilly & Company

20090253624 - Pharmacologically active antiviral peptides and methods of use: This invention relates to peptides having antiviral properties. The antiviral peptides comprise membrane transiting peptides, and active fragments and derivatives of such peptides. The antiviral peptides exhibit activity against a broad spectrum of viruses, including enveloped and nonenveloped viruses, and are used in pharmaceutical compositions to prevent and/or treat viral... Agent: Patent Docket Department Armstrong Teasdale LLP

20090253629 - Use of defensins against meningitis: The present invention relates to methods for treating meningitis, such as bacterial meningitis, with defensin polypeptides.... Agent: Novozymes North America, Inc.

20090253628 - Use of pegylated igf-i variants for the treatment of neuromuscular disorders: The present invention relates to a pharmaceutical composition containing a PEGylated IGF-I variant derived from the wild-type human IGF-I amino acid sequence where one or two of the lysine amino acids at positions 27, 65, and 68 are altered to be a polar amino acid other than lysine and where... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090253622 - Use of tlr3 agonists for the treatment of neurodegenerative disorders: The present invention relates to a method for the treatment and/or prophylaxis of a degenerative inflammatory process in a tissue of a subject, said method comprising increasing the activity of Toll-like receptor 3 (TLR3) in cells of said tissue. In a preferred embodiment, the TLR3 agonist is stathmin or stathmin-like... Agent: Lucas & Mercanti, LLP

20090253631 - Anti-inflammatory peptides: The present invention relates, inter alia, to a method of ameliorating an inflammatory skin condition. Thus, the present invention provides a peptide that includes the amino acid sequence KMIKP (SEQ ID NO: 20), wherein the peptide includes no more than 70 amino acids and wherein the peptide is capable of... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090253633 - Novel combinations of dnak inhibitors with known antibacterial agents: Compositions, methods and kits are provided comprising (a) a therapeutically effective amount of a DnaK inhibitor; and (b) a therapeutically effective amount of a known antibacterial agent. Such compositions, methods and kits are useful in the treatment of various bacterial infections.... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090253632 - Therapeutic peptides and method: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.... Agent: Foley And Lardner LLP Suite 500

20090253634 - Methods and compositions for the treatment of gastrointestinal disorders: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastnoesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction... Agent: Fish & Richardson PC

20090253635 - Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090253636 - Novel antifungal agent: It is intended to provide a novel peptide which can exert higher antifungal effect also on a patient whose organ function is impaired with no side effect problems. The peptide comprises the following amino acid sequence: (1) SEQ ID NO:1: Lys-Arg-Leu-Phe-Arg-Arg-Trp-Gln-Trp-Arg-Tyr, (2) SEQ ID NO:2: Arg-Arg-Trp-Gln-Trp-Arg-Met-Lys-Lys-Tyr, (3) SEQ ID NO:3:... Agent: Birch Stewart Kolasch & Birch

20090253637 - Small peptides for the treatment of alzheimer's disease and other beta-amyloid protein disorders: Use of a peptide or pharmaceutical composition comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating APP processing, modulating activity of APP secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease.... Agent: Proteotech, Inc.

20090253638 - Somatostatin antagonists: The invention features somatostatin antagonists having a D-amino acid at the second residue.... Agent: Biomeasure, Incorporated

20090253639 - Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases: The present invention relates to modified opiorphin peptides as new inhibitors of metallo-ectopeptidases.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090253640 - Inhibitors of polyisoprenylated methylated protein methyl esterase: Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R1-X-A-B(R2)-Y or R1-X-A(R2)-B-Y, where R1 is preferably a polyisoprenyl group, X is a linking group, Y is a group that promotes affinity interactions to the... Agent: ParksIPLaw LLC

20090253641 - Methods for preventing or treating insulin resistance: The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship... Agent: Foley & Lardner LLP

20090253642 - Mimicking the metabolic effects of caloric restriction by administration of glucose anti-metabolites: Methods of maintaining and/or attenuating a decline in the quality of life of a mammal comprising the step of administering to the mammal a composition comprising an effective amount of mannoheptulose wherein the effective amount of mannoheptulose provides a dosage to the mammal on a daily basis from about 0.001... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090253643 - Equol level regulator: An object of the invention is to provide a medical drug, a food and drink having a role in regulating the concentration of equal in vivo and being capable of taking for a long time with high safety and provide a selective medium for a microorganism having conversion ability to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090253644 - Radiosensitizer:

20090253645 - Methods and materials for treating and preventing inflammation of mucosal tissue: The invention involves methods and materials for treating and preventing non-invasive fungus-induced mucositis. Specifically, the invention involves administrating an antifungal agent such that it contact mucus in an amount, at a frequency, and for a duration effective to prevent, reduce, or eliminate non-invasive fungus-induced rhinosinusitis. This invention also provides methods... Agent: Fish & Richardson P.C.

20090253646 - Pan-selectin inhibitor with enhanced pharmacokinetic activity: Compounds, compositions and methods are provided for treatment of diseases or complications associated therewith, in which a selectin plays a role. More specifically, particular glycomimetics and uses thereof are described. For example, use of particular glycomimetics for treating sickle cell disease or a cancer involving a selectin, or complications associated... Agent: Seed Intellectual Property Law Group PLLC

20090253775 - Compositions and methods for therapy and diagnosis of cancer and cancer metastasis: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in... Agent: Mcandrews Held & Malloy, Ltd

20090253771 - Inhibition of gliotoxin: The present invention relates to the inhibition of the interaction between Gliotoxin (GT) and its intracellular target for the prevention and/or treatment of fungal infections. Further, novel methods and systems for identifying antifungal agents are disclosed.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090253769 - Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders: The present invention, relies, in part, on the discovery of the role of HDAC 11 in various cell proliferative disorders including cancer. In the main, the invention provides for methods of inhibiting HDAC 11 as a means of treating cell proliferative disorders. Reagents for use in inhibiting human HDAC 11... Agent: Merck And Co., Inc

20090253772 - Rna interference mediated inhibition of cxcr4 gene expression using short interfering nuceleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating chemokine receptor (CXCR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CXCR gene expression and/or... Agent: Sirna Therapeutics, Inc.

20090253774 - Rna interference mediated inhibition of platelet derived growth factor (pdgf) and platelet derived growth factor receptor (pdgfr) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating platelet derived growth factor (PDGF) and/or platelet derived growth factor receptor (PDGFr) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other... Agent: Sirna Therapeutics, Inc.

20090253773 - Rna interference mediated inhibition of tnf and tnf receptor gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating tumor necrosis factor and/or tumor necrosis factor receptor gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways... Agent: Sirna Therapeutics, Inc.

20090253776 - Sirna targeting gremlin: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed... Agent: Kalow & Springut LLP

20090253770 - Target gene mimitin of myc: A new diagnosis or treatment of cancer is provided. The present invention provides a protein Mimitin which is a target of a cancer gene myc protein, a variant thereof and a fragment thereof, as well as a polynucleotide molecule encoding them. An inhibitory substance of biological activity of the present... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090253780 - Compositions and methods related to mir-16 and therapy of prostate cancer: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-16, using miR-16 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fulbright & Jaworski L.L.P.

20090253778 - Dna composition against tumor stromal antigen fap and methods of use thereof: A DNA composition effective for eliciting an immune response against tumor cells and tumor metastases comprising a DNA construct that encodes for at least one epitope of fibroblast activation protein (FAP), which is expressible in immune cells, and which is incorporated in a pharmaceutically acceptable carrier. The composition can encode... Agent: Olson & Cepuritis, Ltd.

20090253779 - Expression of rbap48 in memory and aging and methods related thereto: This invention provides a method for increasing the expression of RbAp48 protein in a eukaryotic cell comprising introducing into the cell an agent which specifically increases the expression of RbAp48 protein in the cell. This invention also provides a method for treating a subject afflicted with age-related memory decline comprising... Agent: Cooper & Dunham, LLP

20090253777 - Methods of diagnosing and treating hyperproliferative disorders: The invention relates to compositions and methods for diagnosing and treating hyperproliferative disorders using ligands which specifically recognize the hypusine and/or folate binding region of mature eukaryotic translation initiation factor 5A (hypusine-containing eIF-5A). The invention further relates to methods of identifying molecules which displace immunoreagents binding to mature eIF-5A. Such... Agent: Klauber & Jackson

20090253647 - 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity: e

20090253648 - Tricyclic-nucleoside compounds for treating viral infections: Disclosed are compounds represented by formulae I, II, and III, and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus.... Agent: Dority & Manning, P.A.

20090253649 - Agents containing folic acid, vitamin b6 and vitamin b12, and the use thereof: (EN) The invention relates to agents that contain folic acid, vitamin B6 and vitamin B12. and to the use thereof in hyperhomocysteinemia for controlling homocysteine levels. The agents are mainly suitable for the preventive and acute treatment of vascular diseases, of pregnant women and neurodegenerative diseases and are particularly advantageous... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090253651 - Drug delivery system based on regioselectively amidated hyaluronic acid: New drug delivery systems (DDS) are described containing hyaluronic acid and a therapeutic agent, wherein the therapeutic agent is linked, directly or via a linker, to 6-aminohyaluronic acid and where the linkage of the drug or linker with 6-aminohyaluronic acid is realised by an amide bond. Preferred therapeutic agents for... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090253650 - Teat antiseptic prepared from polysaccharide gel with bactericidal and immuno-stimulating activity isolated from durian fruit-rind: A teat antiseptic having bactericidal activity against bacteria causing bovine mastitis. A post-milking teat dip and teat seal were prepared using polysaccharide gel with bactericidal, immuno-stimulating and wound healing activity isolated from durian fruit rind as active ingredient.... Agent: Dr. S. Pongsamart Faculty Of Pharmaceutical Sciences

20090253652 - Phosphate-binding chitosan and uses thereof: The present invention provides compositions and methods for removing phosphate from a subject using chitosan. The present invention also provides compositions and methods for treating hyperphosphatemia based on phosphate-binding chitosan.... Agent: Choate, Hall & Stewart LLP

20090253653 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase... Agent: Foley Hoag, LLP (w/ipx)

20090253654 - Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment: The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally... Agent: Knobbe Martens Olson & Bear LLP

20090253655 - Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications: e

20090253656 - Bcrp/abcg2 inhibitor:

20090253657 - Use of clodronic acid for treatment podotrochlosis: The invention describes the use of clodronic acid, its addition salts or esters as active ingredient for the preparation of a pharmaceutical for treating podotrochlosis with associated osteoporosis in horses.... Agent: The Nath Law Group

20090253658 - Fat accumulation inhibitor: A fat accumulation inhibitor for a fat cell, which comprises a milk-derived phospholipid as an active ingredient, and a food or drink for inhibiting fat accumulation in a fat cell, which comprises a milk-derived phospholipid. A visceral fat accumulation inhibitor comprising a sphingosine-containing phospholipid or a derivative thereof as an... Agent: Morgan Lewis & Bockius LLP

20090253659 - Cycloalkylidene compounds as modulators of estrogen receptor: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel substituted cyclic alkylidene compounds that are particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090253660 - Minocycline compounds and methods of use thereof: Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090253661 - Ocular agents: A method to reduce or ameliorate an ocular condition, such as ocular scarring that may occur after ocular surgery or another non-surgical ocular inflammatory or other condition, by topically administering doxycycline as the sole active agent to a patient in need thereof under conditions to reduce or ameliorate the ocular... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090253664 - Combination andolast/glucocorticoids: The invention relates to the combination of Andolast, a calcium-activated potassium channel opener and glucocorticoids for the treatment of patients suffering for airway diseases. Pharmaceutical compositions comprising Andoalst and glucocorticoids are also disclosed.... Agent: Sughrue Mion, PLLC

20090253662 - Genetic risk assessment in heart failure: impact of genetic variation of aldosterone synthase promoter polymorphism: The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance;... Agent: Wilmerhale/nitromed

20090253665 - Method of treatment of disease using an adenosine a1 receptor antagonist and an aldosterone inhibitor: Pharmaceutical compositions comprising an aldosterone inhibitor and an adenosine A1 receptor antagonist (AA1RA) and methods of treating cardiovascular disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient are disclosed.... Agent: Merck And Co., Inc

20090253663 - Skin external preparation containing triterpenic acid: Disclosed is a skin external preparation containing a triterpenic acid typified by ursolic acid. For obtaining a skin external preparation having excellent storage stability by improving the dissolution stability of the triterpenic acid and the like, 4-alkylresorcinol such as 4-n-butylresorcinol is added into a skin external preparation containing a triterpenic... Agent: Knobbe Martens Olson & Bear LLP

20090253666 - Composition comprising sarsasapogenin: The présent invention relates to a composition comprising sarsasapogenin or a plant extract containing it in order to improve the gêneral state of the skin and in particular to improve and/or embellish any part of the body showing a déficit in lipids. More particularly, the invention is directed to a... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090253667 - 18 ,21-didesoxymacbecin derivatives for the treatment of cancer: The present invention relates to 18,21-didesoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pre-treatment for cancer. The present invention also provides methods for... Agent: Dann, Dorfman, Herrell & Skillman

20090253668 - Hair loss prevention by natural amino acid and peptide complexes: This invention relates to certain skin and hair care agents of formula (I), derived from natural amino acids and peptides. These agents provide multi-functional treatment of enzyme-related skin, hair and scalp problems, for example, hair aging including premature hair loss and hair graying; male pattern baldness; hair loss from dandruff;... Agent: Shyam K. Gupta Bioderm Research

20090253670 - Amide derivatives as positive allosteric modulators and methods of use thereof: The invention relates to novel amide derivatives that are positive allosteric modulators of neuronal nicotinic receptors, compositions comprising the same, processes for preparing such compounds, and methods for using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20090253669 - Substituted sulfonamide compounds: e

20090253672 - Cathepsin cysteine protease inhibitors: This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3, R4, R5, R6, R7, X and Y are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsms K L, S and B... Agent: Merck And Co., Inc

20090253675 - Pharmaceutical formulation: The instant invention provides a pharmaceutical composition comprised of a cholesterol absorption inhibitor and an HMG-CoA reductase inhibitor, one or more anti-oxidants, microcrystalline cellulose, hydroxypropyl methylcellulose, magnesium stearate and lactose. The composition need not contain ascorbic acid in order to obtain desirable stability.... Agent: Foley And Lardner LLP Suite 500

20090253676 - Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes: e

20090253677 - Hiv integrase inhibitors: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with... Agent: Louis J. Wille Bristol-myers Squibb Company

20090253673 - Substituted pyrazoles as ghrelin receptor antagonists: Certain novel N-acylated spiropiperidine derivatives are ligands of the human ghrelin receptor(s) and, in particular, are antagonists/inverse agonists of the human ghrelin receptor. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of the ghrelin receptor, such as obesity, diabetes, and... Agent: Merck And Co., Inc

20090253674 - Substituted triazole derivatives as oxytocin antagonists: The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction.... Agent: Pfizer Inc. Patent Department

20090253671 - Tricyclic derivatives of azetidine and pyrrole with antibacterial activity: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.... Agent: Astrazeneca R&d Boston

20090253678 - Macrocyclic pyrimidine derivatives: Macrocyclic pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions, and disorders using such compounds and compositions are described herein.... Agent: Paul D. Yasger Abbott Laboratories

20090253679 - New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular cdc7: c

20090253680 - Selected cgrp-antagonists, processes for preparing them and their use as pharmaceutical compositions: wherein R1, R2, R3 and R4 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates thereof, the mixtures thereof and the salts thereof and the hydrates of the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases,... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090253681 - Hiv integrase inhibitors: Compounds of Formula I are inhibitors of FHV integrase and inhibitors of FHV replication (I), wherein m, n, X, R1, R2, R3, R4, R5, R6, R7; R8, R9 and R10 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HTV and the prophylaxis, treatment,... Agent: Merck And Co., Inc

20090253682 - Heterocyclic derivatives for modulation of calcium channels: Heterocyclic derivatives act as Ca channel antagonists. The compositions are useful for treating or relieving Ca channel mediated conditions.... Agent: Vertex Pharmaceuticals Inc.

20090253683 - 7-membered ring compound and method of production and pharmaceutical application thereof: t

20090253684 - Leukotriene b4 inhibitors:

20090253685 - Product comprising at least one cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent:

20090253686 - Unsolvated benzodiazepine compositions and methods: The present invention relates to systems and methods for generating new forms of benzodiazepine and benzodiazepine related compounds as well as new compounds and formulations generated by such methods. In particular, the present invention provides high throughput systems and methods for generating and identifying new crystalline benzodiazepine and benzodiazepine related... Agent: Casimir Jones, S.c.

20090253687 - Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands: The present invention relates to wherein each symbol is as defined in the specification. The compound has a superior mineral corticoidreceptorantagonistic action and is useful as an agent for the prophylaxis or treatment of hypertension, cardiac failure and the like, a compound having a fused heterocycle, or a prodrug thereof,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090253688 - Semicarbazide derivatives as kinase inhibitors: The present invention relates to semicarbazide derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition... Agent: Arent Fox LLP

20090253689 - Organic compounds: e

20090253690 - Pharmaceutically effective compounds: The subject invention relates to carboxamidine derivatives, to pharmaceutical compositions containing the carboxamidine derivatives of the invention, and the use thereof for the treatment of vascular diseases and in the preparation of pharmaceutical compositions for the treatment of vascular diseases.... Agent: Ropes & Gray LLP

20090253693 - 2h-benzo[b][1,4]oxazin-3(4h)-one derivatives for use as stearoyl coa desaturase inhibitors: e

20090253692 - Crystalline form of n-[[4-fluoro-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate: Disclosed is a crystalline form of N-[[4-fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-[[4-fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate, and at least one method of using at least one crystalline form of N-[[4-fluoro-2-(5-methyl-1H-1,2,4-triazol-1-yl)phenyl]methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide, sodium salt monohydrate to treat AIDS or... Agent: Louis J. Wille Bristol-myers Squibb Company

20090253691 - Trisubstituted 1,2,4-triazoles: s

20090253694 - Fused hetrocyclic compounds: This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20090253695 - Hydroxyalkyl substituted imidazonaphthyridines: Certain imidazonaphthyridines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.... Agent: Wolf Greenfield & Sacks, P.C.

20090253696 - Substituted pyrido(3,2-d) pyrimidines and pharmaceutical compositions for treating viral infections: This invention provides di-, tri- and tetra-substituted pyrido(3,2-d)pyrimidine derivatives with specific substituting patterns, their pharmaceutically acceptable salts, N-oxides, solvates, pro-drugs and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular being highly active antiviral agents. The invention also provides use of such derivatives in the treatment of viral infections and pathologic... Agent: Clark & Elbing LLP

20090253697 - Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as kdr inhibitors: i

20090253698 - Brain, spinal and nerve injury treatment: A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090253699 - Compounds for nonsense suppression, and methods for their use: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a... Agent: Hoffmann & Baron, LLP

20090253700 - N-'4-4(4-morpholinyl) phenyl!- '(4-piperidinyl) methyl! carboxamide derivatives and their use as glycine transporter inhibitors: e

20090253701 - Organic compounds: and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting... Agent: Novartis Institutes For Biomedical Research, Inc.

20090253702 - Fast acting naratriptan composition: The present invention relates to pharmaceutical compositions containing Naratriptan, a compound selected from the group consisting of 2-HPOD, 2-HPHM, 4-PPED, 4-BPED and 2-PPED, and optionally, a pharmaceutically acceptable excipient.... Agent: Emisphere Technologies, Inc

20090253703 - Organic compounds: and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting... Agent: Novartis Institutes For Biomedical Research, Inc.

20090253704 - Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors: d

20090253705 - Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.... Agent: Merck And Co., Inc

20090253706 - Methods and compositions for the treatment of rheumatoid arthritis and other inflammatory diseases: Compositions and methods for the treatment of inflammatory diseases are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20090253707 - Heteroannelated anthraquinone derivatives and the synthesis method thereof: wherein R1 is a substituent being one selected from a group consisting of i) a first substituent being one selected from a group consisting of a hydryl group, an amino group, a nitro group, a hydroxyl group and a cyan group, ii) a second substituent being one selected from a... Agent: Volpe And Koenig, P.C.

20090253708 - 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and their use as fungicides: This invention relates to certain novel 2-alkynyl-6-pyridin-2-yl-pyridazinones, 2-alkynyl-6-pyridin-2-yl-dihydropyridazinones, 2-alkynyl-6-pyrimidin-2-yl-pyridazinones and 2-alkynyl-6-pyrimidin-2-yl-dihydropyridazinones and to the use of these compounds for control of fungal pathogens of plants and mammals.... Agent: Dow Agrosciences LLC

20090253709 - Synthesis, telomerase inhibition and cytotoxic studies on 2,7-disubstituted anthraquinone derivatives: R is a first substituted group selected from a group consisting of a hydrogen, an amino group, a nitro group, a hydroxyl group, a C1-C12 alkyl group, a C1-C12 alkyl halide group (—(CH2)nX), a C3-C12 cycloalkyl group, a benzyl group, a C1-C12 alkylamino group, a C5-C12 nitrocycloalkyl group and a... Agent: Volpe And Koenig, P.C.

20090253710 - Nmda receptor antagonists for neuroprotection: each (L)k-Ar1 is a substituted or unsubstituted, mono or bicyclic aryl or heteroaryl; W is a bond, alkyl, or alkenyl; X is a bond, NR1 or O and each R1 and R2 is independently H, alkyl, alkenyl or aralkyl or R1 and R2 taken together form a 5-8 membered ring;... Agent: King & Spalding LLP

20090253711 - Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.... Agent: Wyeth Patent Law Group

20090253712 - Aqueous solvent system for solubilization of azole compounds: e

20090253713 - Small molecule compositions for sexual dysfunction: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and X are as defined. Further provided are methods for treatment of sexual dysfunction, including erectile dysfunction and female sexual dysfunction, and combination drugs and method of use thereof, including a compound of the invention and one or more second... Agent: Palatin Technologies, Inc.

20090253714 - Methods of reducing risk of infection from pathogens: Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided comprising administering amiloride, benzamil, phenamil or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to... Agent: Brinks, Hofer, Gilson & Lione

20090253715 - Heteroaryl-containing isoflavones as aromatase inhibitors: wherein X is selected from O, N, S, SO, SO2, and S(CH2)n, wherein n=1-10; R1 and R2 may be the same or different and are selected from H, OH, OCH3, OCH2CH3, OCH2C6H5, NH2, NHCH3, N(CH3)2, CH3, CH2CH3, CH2CH2CH3, CH(CH3)2, C(CH3)3, NO2, F, Cl, Br, CF3, SH, SCH3, SCH2CH3, OCOCH3, OCOC(CH3)3,... Agent: Calfee Halter & Griswold, LLP

20090253716 - Amino-imidazolones for the inhibition of beta-secretase: e

20090253717 - Inhibitors of p97: One aspect of the invention relates to compounds that inhibit the activity of p97, such as by binding covalently to a cysteine residue in the active site. In certain embodiments, the invention relates to the treatment of disease, such as cancer, comprising administering a compound of the invention.... Agent: Ropes & Gray LLP

20090253718 - Pharmaceutical compounds: or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N═C(R6), (R7)C═N, (R8)N—C(O), (R8)2C—C(O), N═N or (R7)C═C(R6); A is an optionally substituted saturated C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length... Agent: Heslin Rothenberg Farley & Mesiti PC

20090253720 - Antifolate compositions: The present invention provides pharmaceutical compositions comprising an antifolate compound. The composition exhibit improved bioavailability, and they particularly incorporate beneficial excipients that increase solubility and bioavailability, such as cyclodextrins or compounds formed of fatty acid esters of glycerol and polyethylene glycol esters. The pharmaceutical compositions are useful in the treatment... Agent: Alston & Bird LLP

20090253721 - Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient a therapeutically effective amount of an EGFR kinase inhibitor, combined with treating the patient simultaneously or sequentially with radiation therapy, with or without additional agents or treatments, such as other... Agent: Osi Pharmaceuticals, Inc.

20090253719 - Crystalline salt forms of antifolate compounds and methods of manufacturing thereof: The present invention provides methods of preparing antifolate compounds. The inventive methods can particularly be use for preparing compounds exhibiting improved bioavailability, making the compound particularly useful in pharmaceutical compositions. The compounds prepared according to the inventive methods are useful in the treatment of multiple conditions, including abnormal cell proliferation,... Agent: Alston & Bird LLP

20090253722 - Aqueous pharmaceutical formulation: The invention concerns a stable aqueous pharmaceutical composition comprising 5-[(2RS)-2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-ylmethyl]-pyrimidine-2,4-diamine in form of the water soluble methanesulfonic acid salt, a physiological sodium chloride solution, ethanol and Povidone 12 PF, the liquid having a pH of over and above 4.8, but not higher than 5.2, and wherein the oxygen amount is... Agent: Dickstein Shapiro LLP

20090253723 - Protein kinase inhibitors: Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090253724 - Therapeutic or prophylactic agent for leukemia: A therapeutic or prophylactic agent for leukemia is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for leukemia according to the present... Agent: Darby & Darby P.C.

20090253725 - Acetyl coa carboxylase inhibitors: t

20090253727 - Nociceptin analogs:

20090253726 - Tri-, tetra-substituted-3-aminopyrrolidine derivative: A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided. The compound provided is represented by formula (I):... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090253729 - Analgesic agent: A pharmaceutical preparation useful for alleviating or treating a pain, e.g., a chronic pain (particularly, a neuropathic pain) is provided. The pharmaceutical preparation contains (a) a propionic acid-derived nonsteroidal anti-inflammatory agent (e.g., ibuprofen), (b) a non-pyrazolone antipyretic analgesic agent (e.g., acetaminophen), and (c) an opioid analgesic agent (e.g., codeine phosphate,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090253730 - Method and composition for deterring abuse of opioid containing dosage forms: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.... Agent: Morgan, Lewis & Bockius LLP

20090253728 - Methods and compositions for treating nociceptive pain: The present invention provides methods and compositions useful for the treatment and prevention of pain.... Agent: Adamas Pharmaceuticals, Inc.

20090253731 - Method of identifying therapeutic agents: The present invention relates to a method of identifying agents suitable for use in treating epilepsy and other brain disorders, including but not limited to bipolar disorder, schizophrenia and depression. The invention further relates to methods of treatment based on the use of agents so identifiable.... Agent: Nixon & Vanderhye, PC

20090253732 - Production of polyketides and other natural products: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. Therefore in aspect the present invention provides 17-desmethylrapamycin and analogues thereof, methods for their production, including recombinant strains, and isolation and uses of the compounds of the invention. In... Agent: Wyeth Patent Law Group

20090253733 - Rapamycin carbonate esters: Certain embodiments include carbonate esters of rapamycin at position 42 that are synthesized by a lipase catalyzed regio-specific process. These compounds or a pharmaceutically acceptable salt thereof are useful in the treatment of organ and tissue transplant rejection, autoimmune disease, proliferative disorder, restenosis, cancer, or microbial infection.... Agent: Dardi & Associates, PLLC

20090253734 - Inhibitors of akt activity: The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in... Agent: Merck And Co., Inc

20090253735 - 2-aryl-6-phenylimidazo[1,2-a]pyridine derivatives, preparation thereof and therapeutic use thereof: e

20090253736 - Azaindole derivatives as cftr modulators: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.... Agent: Vertex Pharmaceuticals Inc.

20090253737 - Certain chemical entities, compositions, and methods: Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of neuromuscular disorders,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090253738 - Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors: o

20090253739 - Amine derivatives:

20090253741 - Alkene piperidine derivatives as antiviral agents: This disclosure provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the disclosure is concerned with alkene piperidine derivatives that possess unique antiviral activity. More particularly, the present disclosure relates to compounds useful for the treatment of HIV and AIDS.... Agent: Louis J. Wille Bristol-myers Squibb Company

20090253740 - Substituted n-bicyclicalkyl bicycliccarboxyamide compounds: This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.... Agent: Pfizer Inc. Patent Department

20090253742 - Marasmius androsaceus l.es fr extract, piperidone derivative, and their use for the preparation of antihypertensives: The present invention relates to Marasmius androsaceus L.es Fr extract, a compound of formula I, or pharmaceutically acceptable salts thereof, and to methods for their preparation, pharmaceutical composition comprising the same as well as use of the extract or the compound in the preparation of a medicament for the prevention... Agent: Alston & Bird LLP

20090253743 - Compositions of tolperisone: The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.... Agent: King & Spalding LLP

20090253744 - Acylated piperidine derivatives as melanocortin-4 receptor modulators: Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction,... Agent: Merck And Co., Inc

20090253745 - Modulators of ocular oxidative stress: Described herein are compounds, compositions and methods directed to the treatment of ophthalmic conditions characterized by oxidative stress or damage in a subject by reducing the reactive oxygen species in the subject. Also described herein are methods for reducing ophthalmic photooxidative damage in a subject.... Agent: Wilson Sonsini Goodrich & Rosati

20090253746 - Synthesis and preparations of intermediates and new polymorphs thereof useful for the preparation of donepezil hydrochlcoride: The invention relates to an improved process for preparing 2-(1-benzylpiperidin-4-ylmethyliden)-5,6-dimethoxyin-dan-1-one (a key intermediate in the synthesis of donepezil hydrochloride), crystalline polymorph forms of this key intermediate and their use thereof for producing donepezil hydrochloride. In particular, the invention provides an improved method for producing the intermediate 2-(1-benzylpiperidin-4-ylmethyliden)-5,6-dimethoxyindan-1-one. The process includes... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20090253747 - Remedy for sleep disturbance: The present invention has been made based on the finding that a compound acting on the ORL-1 receptor as an agonist acts as a non-photic entrainment factor, and advances the circadian rhythm phase, and provides a novel therapeutic agent for a sleep disorder such as circadian rhythm sleep disorder, more... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090253748 - Process for the preparation of pleuromutilins: A process for the preparation of 14-O-[(N-(3-methyl-2-amino-butyryl-piperidinyl)sulfanyl) acetyl]mutilins of formula (I) feasible for large-scale production of high purity products, and wherein the carbon atom at the piperidine ring attached to the sulphur atom is either in the (S)-configuration or in the (R)-configuration, and a new crystalline form of 14-O-[(N-3-methyl-2-(R)-amino-butyryl-piperidine-3(S)-yl)sulfanyl)acetyl]mutilin-hydrochloride.... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090253749 - Substituted enaminocarbonyl compounds: The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090253750 - 3-indazolyl-4-pyridylisothiazoles: The present invention provides 3-indazoyl-4-pyridylisothiazoles or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and methods of using the same, as well as processes for preparing the same, and intermediates thereof.... Agent: Eli Lilly & Company

20090253751 - Hydrazide compound and thrombopoietin receptor activator: e

20090253752 - Combination of dpp-iv inhibitor, ppar antidiabetic and metmorfin: for simultaneous, separate or sequential use, especially in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more particular type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; the... Agent: Novartis Corporate Intellectual Property

20090253753 - Therapeutic use of acylaminothiazole derivatives: r

20090253754 - Fast dissolving films and coatings for controlled release of flavors, active pharmaceutical ingredients, food substances, and nicotine: A fast-dissolving film for use as a platform for the delivery of material to the oral cavity, comprising a film forming agent; a plasticizing agent; and a fast-dissolving, water-soluble agent; and methods for producing same.... Agent: Krieg Devault LLP

20090253755 - N-[(pyridin-2-yl) methoxy] benzamide derivatives and related compounds as fungicides: f

20090253756 - Indole amide derivatives as ep4 receptor antagonists: The invention is directed to indole amide derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis and cancer. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090253757 - Plant protection agents: e

20090253758 - Selective androgen receptor modulators: This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, and or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially treated by an androgen receptor... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090253761 - Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity: Benzocycloheptyl analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors.... Agent: Iplm Group, P.A.

20090253760 - Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity: Hydrindane analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors.... Agent: Iplm Group, P.A.

20090253759 - Tetralin analogs having sphingosine 1-phosphate agonist activity: Tetralin analogs that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs, which, after phosphorylation, can behave as agonists at S1P receptors.... Agent: Iplm Group, P.A.

20090253762 - Preparation and use of aryl alkyl acid derivatives for the treatment of obesity: This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.... Agent: Edwards Angell Palmer & Dodge LLP

20090253763 - Ester compound and its use: i

20090253764 - Use of ampk-activating imidazole derivatives, preparation process therefor and pharmaceutical compositions comprising them:

20090253765 - Angiogenesis inhibitor containing amine derivative as active ingredient: An object of the present invention is to provide an angiogenesis inhibitor. The angiogenesis inhibitor according to the present invention contains a compound represented by the following general formula [I] or a salt thereof as an active ingredient. In the formula, the ring A represents a benzene ring or a... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090253766 - Thiophene derivatives as factor xia inhibitors: or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, L1, R3, and R11 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor... Agent: Louis J. Wille Bristol-myers Squibb Company

20090253767 - Aminoindazolylurea derivatives: Novel aminoindazolylurea derivatives of the formula I (I), in which R1, R2, R3, R4, R5, X and Y have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary... Agent: Millen, White, Zelano & Branigan, P.C.

20090253768 - Therapeutic compounds for diseases and disorders: Pyrrole derivatives are disclosed as agents for the treatment and prevention of neuropathies and neurodegenerative diseases characterized by the presence of axonal blockages, impaired axonal transport or impaired trafficking of vesicles in neurons.... Agent: Myriad Pharmaceuticals, Inc. C/o Cpa Global

20090253781 - Therapeutic compositions: These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the... Agent: Nixon & Vanderhye, PC

20090253782 - Compounds for enhancing arginase activity and methods of use thereof: The present invention relates to a method for enhancing arginase activity in a damaged or injured cell. In other aspects, the invention provides a method for treating a disorder that can be treated by enhancing arginase activity in a human in need thereof, the method comprising administering to the human... Agent: Irving N. Feit Hoffmann & Baron, LLP

20090253783 - Production of delta 9 tetrahydrocannabinol: The present invention provides isolated, purified Δ9 THC. In another embodiment, the invention provides pharmaceutical compositions comprising isolated, purified Δ9 THC and a pharmaceutically acceptable carrier. In another embodiment, the invention provides methods of preparing pharmaceutical compositions comprising isolated, purified Δ9 THC and a pharmaceutically acceptable carrier.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090253784 - Use of 3-(2,4,6-trimethylphenyl)-4-neopentylcarbonyloxy-5,5-tetramethylene- delta3-dihydrofuran-2-one for controlling diptera from the cecidomyiidae family: The present application relates to the use of 3-(2,4,6-trimethylphenyl)-4-neopentylcarbonyloxy-5,5-tetramethylene-Δ3-dihydrofuran-2-one for controlling insects from the family Cecidomyiidae.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090253785 - Bactericide composition: A bactericide composition kills Staphylococcus aureus (S. aureus), Escherichia coli (E. coli), Methicillin-resistant Staphylococcus aureus (MRSA) and Propionibacterium acnes (P. acnes) and comprises a solvent and L-ascorbic acid. The L-ascorbic acid is dissolved in the solvent in a range of 1 wt % to 40 wt %. Ascorbic acid (vitamin... Agent: Andrews Kurth LLP

20090253787 - Short-acting sedative hypnotic agents for anesthesia and sedation: The invention provides compounds compositions and methods useful for inducing or maintaining general anesthesia or sedation in mammals.... Agent: Pepper Hamilton LLP

20090253786 - Synthesis, anti-allergic, anti-asthmatic and anti-inflammatory activities of cee-1 and cee-2: “Enhydrazone esters of formula (I): wherein R is methyl or ethyl group have been synthesized. The compounds of formula (I) are potent inhibitors of degranulation of both mast cells and eosinophils. These compounds also suppress cytokines generation by leukocytes. These biological activities are relevant to the prevention and/or treatment of... Agent: Furr Law Firm

20090253788 - Combinations of adapalene and benzoyl peroxide for treating acne lesions: Adapalene or a pharmaceutically acceptable salt thereof formulated into a pharmaceutical composition is useful for reducing the number of acne lesions, via daily topical application, in combination or in association with benzoyl peroxide (BPO); such treatment may be via administration of a pharmaceutical composition combining adapalene and BPO or by... Agent: Buchanan, Ingersoll & Rooney PC

20090253790 - Dairy composition with probiotics and anti-microbial system: Dairy compositions are provided having a high pH, of about 4.8 to about 6.2, comprising desirable probiotic cultures as well as an anti-microbial system for inhibiting undesirable pathogenic and/or spoilage microbial growth without significantly reducing the beneficial effect of the probiotic cultures.... Agent: Fitch Even Tabin & Flannery

20090253789 - Preventive/remedy for arteriosclerotic disease and method of evaluating therapeutic procedure: There is provided an evaluation method of effect of a remedy or a therapeutic procedure for atherosclerosis directly or indirectly acting on a substance having a nature of exacerbating atherosclerosis (particularly, a protein) and being present in an atherosclerotic lesion to improve the atherosclerotic lesion, which comprises performing an evaluation... Agent: Edwards Angell Palmer & Dodge LLP

20090253791 - Compositions and methods for preventing or treating inflammatory bowel disease: Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid (LA), and α-linoleic acid (ALA) are administered to felines for preventing or treating feline inflammatory bowel disease (IBD).... Agent: Colgate-palmolive Company

20090253792 - Active agent delivery systems and methods for protecting and administering active agents: The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.... Agent: Darby & Darby P.C.

20090253793 - Composition and method for binding acetaldehyde in stomach: This invention relates to a non-toxic composition which bind acetaldehyde present in the stomach, intestine and/or colon. The composition comprises one or more acetaldehyde-binding compound(s) comprising one or more free sulphhydryl and/or amino groups. The compound(s) are mixed with a non-toxic carrier that effects sustained release of said compound(s) in... Agent: Sughrue Mion, PLLC

20090253795 - Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibiton of pain and inflammation: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that demonstrates substantial agonist activity at alpha adrenergic receptors and that is selected for peripheral (local) vasoconstriction and one or more additional pain and inflammation inhibitory agents... Agent: Omeros Medical Systems, Inc.

20090253794 - Fibroblast activator, collagen production promoter, collagen contraction promoter, hyaluronic acid production promoter, atp production promoter, melanin formation inhibitor, and agent for external application to the skin: m

20090253796 - Method for treating vascular disease: A medicament for prophylactic and/or therapeutic treatment of a vascular disease such as vascular restenosis and/or reocclusion after percutaneous transluminal coronary angioplasty using an intravascular stent, which comprises as an active ingredient a substance selected from the group consisting of retinoids and agents for controlling actions of retinoids such as... Agent: Greenblum & Bernstein, P.L.C

20090253797 - Creatine oral supplementation using creatine hydrochloride salt: Creatine oral supplementation using creatine hydrochloride salt, that may be added to a liquid or other beverage, or may be also used as an additive to solid oral dosages, or as a supplement, and which may be consumed by the athlete, or other party looking for immediate supplementation of strength,... Agent: Hanify & King Professional Corporation

20090253798 - Colchicine solid complex; methods of making; and methods of use thereof: Disclosed are new colchicine solid complexes, methods of making the solid complexes as well as formulations prepared therefrom and uses thereof.... Agent: Cantor Colburn, LLP

20090253799 - Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator: Provided herein are divalent hydrazide-polyethylene glycol conjugates that inhibit the ion transport activity of a cystic fibrosis transmembrane conductance regulator (CFTR). The conjugates described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, secretory diarrhea.... Agent: Seed Intellectual Property Law Group PLLC

20090253800 - Interaction control of cationic biocides using labile anionic polyelectrolytes: Methods of inhibiting the uptake of cationic biocides into medical devices such as contact lenses and implants are described. Methods of stabilizing emulsions containing cationic biocides are also described. In particular, the present invention provides for the use of polymers acting as labile anionic polyelectrolytes to reversibly bind cationic biocides.... Agent: Alcon

20090253801 - Novel antiarrhythmic drug formulations: The present invention provides a method of achieving a novel Propafenone formulation, which will have reduced number dosings and improved bioavailability. The present invention also applies to the salt and active metabolites of the parent and pro-drug. The novel compositions are designed to release Propafenone after oral intake in a... Agent: Clements Bernard PLLC

20090253802 - Therapeutic agent for treating liver disease containing 2-amino-1,3-propanediol derivative as active ingredient, and method for treating liver disease: It has been found that a diarylsulfide or diarylether derivative having 2-amino-1,3-propanediol structure, the compound that act as a sphingosine-1-phosphate receptor agonist, and a pharmaceutically acceptable salt and hydrate thereof are used as effective therapeutic agents for various diseases in organs, in particular liver diseases. The diarylsulfide or diarylether derivative... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090253803 - Memantine protects inflammation-related degeneration of dopamine neurons through inhibition of over-activated microglia and release of neurotrophic factors from astroglia: This invention discloses that memantine (MMT) protects dopamine (DA) neurons damage through its potent anti-inflammatory effect by inhibiting microglial over-activation and the protection on DA neuron is a dose-dependent response under an effective amount of lower than 10 mg/kg. This invention also discloses that NADPH oxidase plays a critical role... Agent: Wpat, PC Intellectual Property Attorneys

20090253804 - Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes: Method for the treatment or prophylaxis of dry eye disorders by the administration of alkylamino-polyhydroxyalkanes and compositions thereof.... Agent: Dann, Dorfman, Herrell & Skillman

20090253805 - Photocurable thiol-ene low gas permeability membranes: The present invention provides modified multifunctional thiol-ene monomers wherein one or more thiols are reacted with a Michael addition reactive double bond compound. The present invention further discloses photocurable thiol-ene formulations comprising thiol-ene monomers including the modified multifunctional thiols. The present invention further discloses photocurable thiol-ene formulations comprising thiol-ene monomers... Agent: Howrey LLP-hn

20090253806 - Polyanhydride polymers and their uses in biomedical devices: A biocompatible, bioerodable polyanhydride polymer having a Young's modulus between about 1.5 and 3 and a selected rate of surface degradation, and methods of forming and using the polymer, are disclosed. The polymer is formed of a polyester prepolymer having a preferred molecular weight of greater than 5 and less... Agent: King & Spalding LLP

20090253807 - Aqueous suspension preparations: Addition of polyvinylpyrrolidone and a water-soluble anionic macromolecular compound to an aqueous suspension of a hardly soluble drug allows to provide an aqueous suspension in which aggregation of drug particles, formation of macro crystals from suspended particles and formation of secondary particles from deposited particles are prevented, and adhesion and... Agent: Merchant & Gould PC

20090253808 - Tri-molecular complexes and their use in drug delivery systems: This invention relates to macromolecular complexes useful in drug delivery systems, specifically tri-molecular complexes made between a water-soluble polymer and an acid-insoluble polymer in presence of a bridging molecule. In one aspect, the invention relates to a tri-molecular complex comprising gelatin, acrylic acid/methacrylic acid copolymers, and arginine for use in... Agent: Leydig Voit & Mayer, Ltd

20090253809 - Bioabsorbable elastomeric polymer networks, cross-linkers and methods of use: The invention provides elastomeric polymer networks and semi-interpenetrating networks in which a linear PEA, PEUR or PEU polymer is crosslinked by ester or alpha-amino-acid containing cross-linkers that polymerize upon exposure to active species. Bioabsorbable elastomeric internal fixation devices fabricated using such polymer networks and semi-interpenetrating networks are useful for in... Agent: Dla Piper LLP (us)

20090253810 - Osteoinductive putties and methods of making and using such putties: The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and... Agent: Regeneration Technologies, Inc. C/o Mcandrews, Held & Malloy

20090253811 - Manufacture process of organic compounds: The present invention relates to a method of preparing N-substituted salicylamides or derivatives thereof, and their salts, hydrates and solvates. In particular, the present invention relates to a method of preparing N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC) and its corresponding disodium monohydrate.... Agent: Novartis Corporate Intellectual Property

20090253812 - Spider esters as delivery systems: The present invention is directed to the delivery of a variety of topically active materials from a class of compounds called spider esters, which are the topic of U.S. Pat. No. 7,437,707 incorporated herein by reference. According to this first aspect of the present invention, active ingredients are delivered more... Agent: Anthony O'lenick

  
10/01/2009 > patent applications in patent subcategories. categorized by USPTO classification

20090247450 - G-csf liquid formulation: The invention relates to G-CSF liquid formulations that have a long shelf-life and to methods for producing the same. The invention also relates to liquid formulations containing G-CSF as the active substance, acetate as the buffer substance, polysorbate 20 or polysorbate 80 as the surfactant and optionally pharmaceutically acceptable adjuvants,... Agent: Knobbe Martens Olson & Bear LLP

20090247451 - Therapeutic compositions for age-related macular degeneration: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.... Agent: Townsend And Townsend And Crew, LLP

20090247452 - Pharmaceutical formulations for reducing pain: The present invention is direct to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyil, buprenorphine, and sufentanil, or its pharmaceutically... Agent: Howrey LLP-ca

20090247453 - Kallikrein inhibitors and anti-thrombolytic agents and uses thereof: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion... Agent: Lando & Anastasi, LLP

20090247456 - Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy: The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.... Agent: Jones Day

20090247458 - Compositions and methods for treating cystic fibrosis: Particular aspects provide electrokinetically-generated fluids (e.g., electrokinetically-generated gas-enriched fluids and solutions), and therapeutic compositions and methods comprising use thereof in treating at least one symptom of cystic fibrosis. In particular embodiments, at least one symptom of cystic fibrosis treated by the present invention include inhibition of Pseudomonas infection, synergy with... Agent: Davis Wright Tremaine, LLP/seattle

20090247462 - Fgf variants and methods for use thereof: The present invention provides fibroblast growth factor variants demonstrating enhanced receptor subtype specificity and/or affinity. Preferred embodiments include both variants having enhanced activity that act as improved agonists and variants having reduced activity that act as antagonists. Methods of utilizing preferred FGF variants in preparation of medicaments for the treatment... Agent: Winston & Strawn LLP Patent Department

20090247460 - Inhibitor of vascular endothelial cell growth factor: The vascular endothelial cell growth factor (VEGF) inhibitors of the present invention are naturally occurring or recombinantly engineered soluble forms with or without a C-terminal transmembrane region of the receptor for VEGF, a very selective growth factor for endothelial cells. The soluble forms of the receptors will bind the growth... Agent: Merck And Co., Inc

20090247455 - Isolation of inhibitors of ires-mediated translation: The present invention relates to a method for identifying or determining a compound that inhibits or reduces internal ribosome entry site (IRES) mediated translation. For example, the present invention provides a method for determining a compound that inhibits IRES-mediated translation, said method comprising expressing in a cell a counter selectable... Agent: Fenwick & West LLP

20090247454 - Method for detecting a predisposition to develop gestational diabetes mellitus and treatment for this disease: Methods and kits for detecting a predisposition to develop gestational diabetes mellitus and pharmacological treatment for this disease.... Agent: Berenbaum, Weinshienk & Eason, P.c

20090247461 - Methods for therapeutic treatment of pain: A medicament for therapeutic and/or prophylactic treatment of pain such as neuropathic pain that occurs after peripheral or central nerve injury, which contains ginsenoside Rb1 as an active ingredient.... Agent: Greenblum & Bernstein, P.L.C

20090247459 - Modified recombinant factor viii and von willebrand factor and methods of use: The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors. Conjugated coagulation proteins, including compositions and formulations thereof, are also provided by the present... Agent: Baxter Healthcare Corporation

20090247457 - Neurotrophic components of the adnf i complex: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing... Agent: Townsend And Townsend And Crew, LLP

20090247463 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20090247464 - Compositions and methods for topical application and transdermal delivery of an oligopeptide: The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably... Agent: King & Spalding

20090247465 - Novel use of bivalirudin in the treatment of acute coronary syndrome: A method of treating acute coronary syndrome (ACS) in a patient, comprising administering a therapeutically effective amount of an indirect thrombin inhibitor to the patient, and subsequently administering a therapeutically effective amount of a direct thrombin inhibitor to the patient wherein the direct thrombin inhibitor is administered prior to and... Agent: Gibbons P.c.

20090247466 - Neuroprotective integrin-binding peptide and angiopoietin-1 treatments: The present invention provides therapeutic compositions, kits and methods for treating nervous system injury in a mammal. Certain methods include administering to a mammal in need of such therapy an effective amount of angiopoietin-1 (Ang-1), or a functional analog thereof. Certain methods include administering a peptide having 4 to 20... Agent: Viksnins Harris & Padys Pllp

20090247467 - Peptide epitopes of vegfr-2/kdr that inhibit angiogenesis: The disclosure provides antigenic peptides of Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)/KDR. Pharmaceutical compositions including the peptides and/or antigen presenting cells that exhibit the VEGFR-2/KDR peptides on their cell surface are also provided. Methods for eliciting an immune response and for inhibiting angiogenesis by administering such pharmaceutical compositions are provided.... Agent: Klarquist Sparkman, LLP

20090247468 - Pharmaceutical compositions: Methods of spray drying are described.... Agent: Vertex Pharmaceuticals Inc.

20090247474 - 3-aminopyrrolidine derivatives as modulators of chemokine receptors: (wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The... Agent: Fish & Richardson Pc

20090247473 - Acythiols and component thiol compositions as anti-hiv and anti-retroviral agents: Certain thiol and acylthiol compounds inhibit retrovirus growth by attacking the highly conserved zinc finger regions of essential viral proteins. These compounds, compositions containing them, and methods of using them to treat retroviral infections such as HIV are described. These compounds are also useful for preparation of vaccines comprised of... Agent: Townsend And Townsend And Crew, LLP

20090247471 - Inhibitors of cruzipain and other cysteine proteases: r

20090247469 - Ophthalmic compositions comprising a dipeptide: An ophthalmic composition comprising one or more antimicrobial components and a dipeptide. The dipeptide comprises a glycine moiety and another amino acid moiety other than glycine. The ophthalmic compositions include contact lens care solutions for cleaning and disinfecting contact lenses.... Agent: Bausch & Lomb Incorporated

20090247470 - Phenylalanine dipeptide derivatives, compositions and use thereof: Disclosed are a compound of formula I, stereoisomers, pharmaceutically acceptable salts or hydrates thereof, a pharmaceutical composition comprising the smae, a process for preparing the same and use thereof. The compound may also be used to prepare a medicament to treat viral infections, especially to prepare a medicament to treat... Agent: Darby & Darby P.c.

20090247472 - Type 1, 4-naphtoquinone compounds, compositions comprising them and use of these compounds as anti-cancer agents: This invention relates to compounds with the formula (I) given below or one of their pharmaceutically acceptable salts, as a medicine; Formula (I) of pharmaceutical compositions comprising one or more compounds with Formula (I) as active constituent, use of compounds with Formula (I) for the preparation of compositions designed to... Agent: Bachman & Lapointe, P.c.

20090247476 - Mannitol and/or proline for prevention and treatment of ageing related symptoms: The current invention provides new methods and means for the prevention and treatment of ageing-related symptoms and diseases. The invention discloses mannitol 5 and/or proline containing compositions that are particularly useful for the treatment of premature ageing related symptoms in mammalian subjects suffering from genetic defects in DNA damage response... Agent: Swanson & Bratschun, L.l.c.

20090247475 - Methods and compositions relating to pharmacogenetics of different gene variants in the context of irinotecan-based therapies: The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs.... Agent: Fulbright & Jaworski L.l.p.

20090247477 - Methods of suppressing uv light-induced skin carcinogenesis: Administration of the isothiocyanate protects against UV light-induced skin carcinogenesis. In particular, topical application or dietary administration of isothiocyanate sulforaphane after exposure to UV radiation provides effective protection against skin tumor formation. Sulforaphane analogs and glucosinolates also can be employed. Lotions useful for suppressing UV light-induced skin carcinogenesis also are... Agent: Foley And Lardner LLP Suite 500

20090247478 - Novel macrolides and ketolides having antimicrobial activity: The present invention provides compounds having antimicrobial activity for preventing and treating diseases caused by microbial infections. Thus, the present invention relates to novel semi-synthetic 11,12-γ lactone macrolides and ketolides having antimicrobial activity, processes for making compounds as well as pharmaceutical compositions containing said compounds as active ingredients and methods... Agent: Bio Intellectual Property Services (bio Ips) Llc

20090247479 - Therapeutic use of methionine to reduce the toxicity of aminoglycoside antibiotics: Methods of preventing or reducing ototoxicity in patients undergoing treatment with therapeutically effective amounts of aminoglycoside antibiotics are provided. The methods comprise administering an effective amount of an otoprotective agent comprising methionine or a methionine-like moiety to said patient prior to, simultaneously with, or subsequently to administration of the aminoglycoside... Agent: Siu School Of Medicine Office Of Technology Transfer

20090247480 - Anti-cancer therapies: Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.... Agent: Townsend And Townsend And Crew, LLP

20090247481 - Compositions and kits for treating influenza: Compositions, kits and methods are provided for the treatment or prophylaxis of influenza.... Agent: Adamas Pharmaceuticals, Inc.

20090247482 - 50 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090247607 - Dsrna compositions and methods for treating hpv infection: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of... Agent: Novartis Corporate Intellectual Property

20090247610 - Integrase cofactor: The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules.... Agent: Clark & Elbing LLP

20090247611 - Method of treating a cancer with a survivin antisense oligonucleotide and paclitaxel: Provided is a method of treating cancer of the stomach, comprising administering to a patient a therapeutically effective combination of a Survivin antisense oligonucleotide and paclitaxel.... Agent: Eli Lilly & Company

20090247606 - Rna interference mediated inhibition of adenosine a1 receptor (adora1) gene expression using short interfering nucleic acid (sina): The present invention concerns methods and reagents useful in modulating adenosine A1 receptor (ADORA1) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against ADORA1... Agent: Sirna Therapeutics, Inc.

20090247604 - Rnai therapeutics for treatment of eye neovascularization diseases: Compositions and methods for treating ocular disease are provided. Specifically, siRNA molecules and mixtures of siRNA molecules are provided that inhibit angiogenesis and/or neovascularization. The compositions and methods are suitable for treating ocular diseases associated with angiogenesis and/or neovascularization.... Agent: Ropes & Gray LLP

20090247609 - Sm-protein based secretion engineering: The present invention concerns the field of cell culture technology. It describes a novel method for enhancing the secretory transport of proteins in eukaryotic cells by heterologous expression of Munc18c, Sly1 or other members of the SM protein family. This method is particularly useful for the generation of optimized host... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090247608 - Targeting lipids: where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that... Agent: Lando & Anastasi, LLP

20090247605 - Treating diseases mediated by metalloprotease-shed proteins: This invention relates to the identification of membrane-associated proteins shed by metalloproteinases and in particular by TNF-alpha converting enzyme (TACE), to the use of such metalloproteinase-shed proteins in assays for TACE agonists and antagonists, and to the use of metalloproteinase agonists and antagonists, and particularly TACE agonists and antagonists, in... Agent: Immunex Corporation Law Department

20090247614 - Folate conjugates: i

20090247612 - Prevention of viral infectivity: The present invention concerns the inactivation of viral infectivity in a cell-free environment as well as the preparation of a pharmaceutical agent and a method therefore. According to the invention the use of a sequence of oligodeoxynucleotides or oligoribonucleotides or a chimera or a combination thereof capable of binding to... Agent: Joyce Von Natzmer Pequignot + Myers Llc

20090247613 - Rna interference mediated inhibition of b-cell cll/lymphoma-2 (bcl2) gene expression using short interfering nucleic acid (sina): This invention relates to compounds, compositions, and methods useful for modulating BCL2 gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of BCL2 gene expression and/or activity by... Agent: Sirna Therapeutics, Inc.

20090247615 - Triggered rnai: The present application relates to methods and compositions for triggering RNAi. Triggered RNAi is highly versatile because the silencing targets are independent of the detection targets. In some embodiments, methods of silencing or modulating the expression of a target gene are provided. The methods generally comprise providing an initiator to... Agent: Knobbe Martens Olson & Bear LLP

20090247483 - Method for treatment of macular degeneration: Provided is a method of treating or preventing age-related macular degeneration (AMD) in a patient subject to, or symptomatic of the disease, wherein the method comprises restoring normal lysosomal pH (pHL), or acidifying an abnormally elevated pHL, thus decreasing or preventing a damaging accumulation of lipofuscin or waste products in... Agent: Montgomery, Mccracken, Walker & Rhoads, LLP

20090247484 - Compounds: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090247485 - Barrier film-forming compositions and methods of use: Long-lasting persistent, uniform, film-forming skin protecting compositions provide long-lasting persistent barrier films when applied to skin. The compositions have particular utility as barrier teat dips for protecting cows against mastitis and as wound care agents. A barrier film-forming agent is selected from pullulan, pullulan derivatives and combinations thereof. The barrier... Agent: Lathrop & Gage LLP

20090247486 - Composition for oral substance coating, covering material for oral substance, edible container and oral substance using the same: A composition for oral substance coating, a covering material for an oral substance or an edible container, includes an indigestible and water-insoluble dietary fiber derived from a plant, alga or fungus, or a hemicellulose or protopectin, and an oral substance uses the same.... Agent: Birch Stewart Kolasch & Birch

20090247487 - Combination therapy to treat hepatitis b virus: The present invention is directed to a method for treating hepatitis B virus infection in humans comprising administering a synergistically effective amount of agents having known anti-hepatitis B virus activity in combination or alternation. Specifically, the invention is directed to a method for treating hepatitis B virus infection comprising administering... Agent: King & Spalding

20090247488 - Anti-inflammatory phosphonate compounds: The invention is related to phosphorus substituted anti-inflammatory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Viksnins Harris & Padys Pllp

20090247489 - Dihydroxyl compounds and compositions for cholesterol management and related uses: The present invention relates to novel dihydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence,... Agent: Brinks Hofer Gilson & Lione

20090247490 - Topical compositions containing phosphorylated polyphenols: The present invention provides topical compositions containing phosphorylated polyphenols in combination with a topically acceptable carrier. The compositions of the invention provide a means for delayed delivery of the polyphenol to keratinous tissues, such as skin, hair and nails, with enzymes of the keratinous tissue dephosphorylating the polyphenol, and returning... Agent: The Estee Lauder Cos, Inc

20090247491 - Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof: The present invention relates to a composition for prevention and/or treatment of metabolic diseases of bones comprising at least one bisphosphonate; viscosity agents comprising carboxymethylcellulose and xanthan gum; at least one flavouring agent; and purified water; a process for preparing a composition according to the present invention; and use of... Agent: Patent Central Llc Stephan A. Pendorf

20090247492 - Manganese based organometallic complexes, pharmaceutical compositions and dietetic products: The invention relates to compounds and their uses, particularly in the pharmaceutical and dietetic industries. The invention discloses complexes having Mn-SOD like activities, as well as methods for treating various diseases associated with oxidative stress, including cancer and inflammatory conditions, by administering said compounds. It further deals with pharmaceutical compositions... Agent: Nixon & Vanderhye, Pc

20090247493 - Regimens for treatment of conditions related to estrogen deficiency: The present invention relates to methods of stimulating estrogen production that can be used to treat peri-menopausal or estrogen deficiency conditions utilizing regimens involving administration of estrogen and progestin, followed by a hormone-free period.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090247494 - Omega-3 essential fatty acid composition and method for treatment of anal and colon-rectal disorders: I have developed a unique pharmaceutical composition containing Omega-3 essential fatty acids and advantageously an optional corticosteroid and/or topical anesthetic. The composition is useful in a method for treating anal disorders such as fissures and ulcers, hemorrhoids, pruritis ani, and colon-rectal disorders such as procto-sigmoiditis by topical application to or... Agent: Phillip Kofsky

20090247495 - Cucurbitacin b and uses thereof: The present invention relates to uses of cucurbitacins and compositions comprising cucurbitacin B. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof cucurbitacin B. The invention also encompass methods of developing a therapeutic that comprises a... Agent: Wilkinson & Grist

20090247496 - Pharmaceutical composition and extract of poria for enhancing uptake of nutrients: e

20090247497 - Formulation and use of ergosta-7,22-dien-3beta-ol: An isolated and purified form of ergosta-7,22-dien-3β-ol and its use as a marker for identifying Coriolus versicolor (Yunzhi) are provided. A composition used for treatment of cancer and other related diseases or disorders comprising ergosta-7,22-dien-3β-ol is also provided.... Agent: Eagle Ip Limited

20090247498 - Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications: Compositions having an effective amount of an antibacterial agent may be useful in the treatment of amyotrophic lateral sclerosis (ALS) and other diseases of the nervous system. The compositions may include an extraordinary amount of an antibacterial agent. Ceftriaxone has stopped the progression of ALS for a second time after... Agent: Haugen Law Firm

20090247499 - Sulfonylated piperazines as cannabinoid-1 receptor modulators: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20090247501 - Protein kinase inhibitors: Pyrimidine- and triazine-based chemical compounds that are useful, for example, as protein kinase inhibitors for treating cancer, neurological disorders, autoimmune disorders, and other diseases, and methods of using such compounds... Agent: Woodcock Washburn LLP

20090247502 - Substituted pyridoxazines: and prodrugs, stereoisomers, racemates, salts, hydrates, solvates, acid salt hydrates and isomorphic crystalline forms thereof, wherein A, Y and the groups R1, R2, R3 and R4 are defined in the specification. These compounds can be administered in pharmaceutical formulations to modulate cannabinoid receptor activity for the prevention and treatment of... Agent: Cara Therapeutics, Inc. Intellectual Property Department

20090247503 - 5-demethoxyfumagillol and derivatives thereof: Provided herein are 5-demethoxyfumagillol and its derivatives. Also provided herein are methods of making the 5-demethoxyfumagillol and derivatives. Also provided herein are biological activities of the 5-demethoxyfumagillol and derivatives and methods of using same for treating diseases.... Agent: Jones Day

20090247500 - Novel compounds as cannabinoid receptor ligands: o

20090247504 - Indazole derivatives for treatment of alzheimer's disease: Compounds of formula (IA) and (IB) are inhibitors of MARK, and hence are suitable for treatment of Alzheimer's disease.... Agent: Merck And Co., Inc

20090247505 - Spiro(5.5)undecane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247506 - Antibacterial agents: e

20090247508 - Benzoimidazole compounds: Benzoimidazole compounds, compositions, and methods of using them in leukocyte recruitment inhibition, in modulating H4 receptor, and in treating conditions such as inflammation, H4 receptor-mediated conditions, and related conditions.... Agent: Philip S. Johnson Johnson & Johnson

20090247507 - Enzyme inhibitors: Compounds of formula (I), are aurora kinase inhibitors: wherein X is —N—, —CH2—N—, —CH2—CH—, or —CH—; R1 is a radical of formula (IA) wherein Z is —CH2—, —NH—, -0-, —S(O)— —S—, —S(O)2 or a divalent monocyclic carbocyclic or heterocyclic radical having 3-7 ring atoms; Alk is an optionally substituted divalent... Agent: Banner & Witcoff, Ltd.

20090247509 - Novel heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090247510 - Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary hypertension: The present invention relates to the use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension or pulmonary hypertension.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090247511 - Synergistic insecticide and fungicide mixtures: e

20090247512 - Macrocylic inhibitors of hepatitis c virus:

20090247513 - Benzothiophene compounds having antiinfective activity:

20090247514 - Spirolactam aryl cgrp receptor antagonists: (wherein variables A1, A2, A3, A4, A5, A6, A7, E1, E2, E3, E4, E5, G1, G2, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The... Agent: Merck And Co., Inc

20090247515 - 11 beta-hsd1 modulators: h

20090247516 - 3- (benzo [d] [1,3] dioxol-5-ylmethyl) -4- (thio) oxo-2- (thio) oxo-azolidin-5-ylidene derivatives as antibacterial agents: The present invention concerns novel azolidine compounds of Formula (I) wherein X denotes S, NH, CH2 or O, Y and W denotes each independently S or O, Q denotes CH or N, n and m are an integer from 0 to 2, and R1 and R2 denote independently from each... Agent: Manelli Denison & Selter

20090247518 - 6-(2-alkyl-phenyl)-pyrido[2,3-d]pyrimidines useful as protein kinase inhibitors: e

20090247517 - Compounds and compositions as inhibitors of cannabinoid receptor 1 activity: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).... Agent: Novartis Corporate Intellectual Property

20090247519 - Amino-ethyl-amino-aryl (aeaa) compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions,... Agent: Michael Best & Friedrich LLP

20090247520 - Inhibitors of antigen receptor-induced nf-kappa b activation: A method to identify selective inhibitors of antigen receptor-mediated NF-κB activation is provided, as well as compositions having one or more of those inhibitors and methods of using those inhibitors.... Agent: Techlaw LLP 10755 Scripps Poway Parkway

20090247522 - Hsp90 family protein inhibitors: (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or... Agent: Fitzpatrick Cella Harper & Scinto

20090247521 - Soluble epoxide hydrolase inhibitors for the treatment of endothelial dysfunction: The present invention generally relates to methods useful for a therapy using a class of urea or amide compounds and related compositions, wherein the compound is a soluble epoxide hydrolase inhibitor, for treating and ameliorating the symptoms of diseases related to endothelial dysfunction.... Agent: Foley & Lardner LLP

20090247523 - Carboxamide 4-[(4-pyridyl)amino]pyrimidines useful as hcv inhibitors: The present invention relates to the use of carboxamide 4-[(4-pyridyl)amino]-pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections.... Agent: Philip S. Johnson Johnson & Johnson

20090247524 - Hsp90 inhibitor: Compounds represented by formula (1) shown below, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising such compounds are provided.... Agent: Fish & Richardson Pc

20090247525 - Sigma receptor inhibitors: m

20090247526 - Glucokinase activators: wherein R2, L, Z, Y, G and R1 are as defined herein, that are useful in the treatment and/or prevention of diseases or disorders mediated by deficient levels of glucokinase activity or which can be treated by activating glucokinase including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG... Agent: Viksnins Harris & Padys Pllp

20090247527 - Substituted gamma lactams as therapeutic agents: e

20090247528 - Method of treating attention deficit disorder: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about... Agent: Pfizer Inc. Patent Department

20090247529 - Topical compositions: Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present... Agent: Dr. Reddy''s Laboratories, Inc.

20090247530 - Substituted 4-aminocyclohexane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247531 - Crystalline forms of [(1r), 2s]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester: Crystalline form, Form N-1, of [(1R),2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising the Form N-1 of Compound I as well as a method of using the Form N-1 of Compound I in the treatment of cancer and... Agent: Louis J. Wille Bristol-myers Squibb Company

20090247532 - Crystalline polymorph of sitagliptin phosphate and its preparation: The present invention is directed to a novel polymorph form of crystalline sitagliptin phosphate, named as Form V herein. The present invention further provides processes for preparations of Form V, pharmaceutical composition comprising Form V and its use in therapy. Form V can be prepared from recrystallizing sitagliptin phosphate in... Agent: Mae De Ltd.

20090247533 - Ecteinascidins: The present invention is directed to several newly discovered ecteinascidin (Et) species, designated herein as Et 731, Et 815, Et 808, and Et 594. The physical properties of these compounds, their preparation and therapeutic properties are also reported.... Agent: King & Spalding

20090247534 - New compounds: e

20090247535 - Use of ranolazine for non-cardiovascular disorders:

20090247536 - Bissulfonamide compounds as agonists of galr1, compositions, and methods of use: Embodiments of the present invention provide bissulfonamide compounds that are agonists of GalR1. The present invention further provides compositions comprising bissulfonamide compounds that are agonists of GalR1, and methods of use of such compounds and compositions.... Agent: Kilpatrick Stockton LLP - 41305 Charles Calkins

20090247537 - Methods for preventing or treating bruxism using dopaminergic agents: Methods for preventing or treating bruxism, including alleviating or eliminating one or more symptoms, diseases or conditions associated with or resulting from bruxism, using dopaminergic agents such as monoamine oxidase inhibitors that increase dopaminergic activity and dopamine agonists, are disclosed.... Agent: Black Lowe & Graham, Pllc

20090247539 - Novel pharmaceuticals: This invention relates to compounds of formula (I)... Agent: Pfizer Inc. Patent Department

20090247538 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors: The invention provides a compound for use as a protein kinase B inhibitor, the compound being a compound of the formula (I) or salts, solvates, tautomers or N-oxides thereof, wherein T is N or CR5; J1-J2 is N═C(R6), (R7)C═N, (R8)N—C(O), (R8)2C—C(O), N═N or (R7)C═C(R6); E is a monocyclic carbocyclic or... Agent: Heslin Rothenberg Farley & Mesiti Pc

20090247540 - Peptide and small molecule agonists of epha and their uses: Methods and compositions for activating an EphA receptor can be used for identifying therapeutic agents for cancer.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20090247541 - Novel compounds: wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090247542 - Syntheses and preparations of polymorphs of crystalline aripiprazole: The invention relates to polymorphic crystalline forms of aripiprazole, synthetic processes for their preparation and pharmaceutical compositions containing the same. These crystalline forms of aripiprazole can be readily milled and can be easily combined with various pharmaceutical adjuvants without effecting changes to their crystalline structure when, for example, pressed into... Agent: Hogan & Hartson LLP Ip Group, Columbia Square

20090247543 - Gatifloxacin-containing aqueous liquid preparation: There is provided an aqueous liquid preparation comprising Gatifloxacin or a pharmacologically acceptable salt thereof or a hydrate thereof, phosphoric acid or a salt thereof, and xanthan gum, wherein a pH thereof is 5.5 or more and less than 7.0. The aqueous liquid preparation has improved intraocular penetration of Gatifloxacin.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090247544 - Certain chemical entities, compositions and methods: Certain substituted urea derivatives modulate diskeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and are useful in the treatment of obesity, sarcopenia, wasting syndrome, frailty, muscle spasm, cachexia, neuromuscular... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090247545 - Substituted oxazolidinone derivatives: The present invention provides substituted oxazolidinone derivatives, which can be used as antimicrobial agents. Compounds disclosed can be used for the treatment or prevention of a condition caused by or contributed to by bacteria, such as, inter alia, multiply-resistant Staphylococci, Streptococci, Enterococci, Bacterioides spp., Clostridium spp., Mycobacterium spp. Bacillus spp.,... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090247546 - Treatment of prevention of valvular heart disease with flibanserin: The invention relates to a method for the treatment or prevention of Valvular Heart Disease comprising the administration of a therapeutically effective amount of flibanserin.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090247547 - Hydroxamate-based inhibitors of deacetylases b: e

20090247550 - 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as hdl-cholesterol raising agents:

20090247549 - Methods of using saha and bortezomib for treating cancer: The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second... Agent: Merck And Co., Inc

20090247548 - Pyrrolopyrimidine derivatives for treating proliferative diseases: e

20090247551 - Substituted enaminocarbonyl compounds: The present invention relates to novel substituted enaminocarbonyl compounds, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, Pc

20090247552 - Aqueous liquid preparation containing amide compound: e

20090247553 - Highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity: Provided herein is a highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-7,8-dihydro-6H-pyrido[1,2-a]pyrimidin-4,9-dione, a process for the preparation thereof, and pharmaceutical compositions comprising highly pure paliperidone or a pharmaceutically acceptable salt thereof substantially free of keto impurity.... Agent: Cantor Colburn, LLP

20090247555 - 5,7-disubstituted[1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives 258: wherein R1, R2, R3, R4, R5, R6, and R7 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1 receptor antagonists and are thereby particularly useful in... Agent: Pepper Hamilton LLP

20090247554 - Kinase inhibitors: Compounds are provided for use with kinases that comprise (I), (II), (III), (IV): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.... Agent: Takeda San Diego, Inc.

20090247556 - Azolopyrimidines as inhibitors of cannabinoid 1 activity: The invention provides compounds of formula (Ia), (Ic), (Ig) and (Ik), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (CB1).... Agent: Genomics Institute Of The Novartis Research Foundation

20090247557 - Partial and full agonists of a1 adenosine receptors: e

20090247558 - Use of the crh (corticotropin releasing hormone) - ucn (urocortin) system in the treatment of inflammatory diseases: The invention relates to the use of corticotropin-releasing hormone (CRH) receptor-1 (R1) antagonists and/or CRH-R2 receptor agonists for the treatment of inflammatory diseases via regulation of monocyte/macrophage cell activation, proliferation, differentiation, apoptosis, and inflammatory cytokine production. As CRH system we define natural and synthetic CRH and urocortin (UCN) agonists and... Agent: Sughrue Mion, Pllc

20090247559 - Benzofuropyrimidinones: e

20090247560 - Diaryl ketimine derivative: [wherein R1a and R1b are the same or different, representing a hydrogen atom, etc.; R2a and R2b are the same or different, representing a hydrogen atom, etc., or R2a and R2b, taken together, form —CH2CH2—, R3a and R3b are the same or different, representing a hydrogen atom, etc.; or R3a... Agent: Merck And Co., Inc

20090247561 - Substituted spirocyclic cyclohexane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247562 - Large substituent, non-phenolic opioids and methods of use thereof: e

20090247564 - Crystalline form of vinflunine ditartrate: The present invention relates to a novel crystalline form of vinflunine, to a process for preparing it, and to its uses in the therapeutic field, in particular for treating cancer.... Agent: Birch Stewart Kolasch & Birch

20090247563 - Novel processes for the production of useful intermediates: The present application relates to a new process for the asymmetric production of 3-(pyridin-4-yl)-3-hydroxy-pentanoic acid derivatives, which are useful intermediates in the manufacture of compounds that are known to show antiproliferative activity.... Agent: Hunton & Williams LLP Intellectual Property Department

20090247567 - Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use: Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using... Agent: Viksnins Harris & Padys Pllp

20090247566 - Pyrano [3,2-c] pyridones and related heterocyclic compounds as pharmaceutical agents for treating disorders responsive to apoptosis, antiproliferation or vascular disruption, and the use thereof: n

20090247565 - Tyrosine kinase inhibitors: The present invention relates to imidazo[1,2-a]pyrimidine derivatives, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090247568 - Aminopiperidinyl derivatives and uses thereof: e

20090247569 - Process for preparing clopidogrel bisulphate: Provided are processes for the preparation of clopidogrel bisulphate Form I.... Agent: Kenyon & Kenyon LLP

20090247571 - Certain chemical entities, compositions and methods: Provided are certain chemical entities, and methods of use to modulate skeletal myosin, skeletal actin, skeletal tropomyosin, skeletal troponin C, skeletal troponin I, skeletal troponin T, and skeletal muscle, including fragments and isoforms thereof, as well as the skeletal sarcomere, and methods of use in the treatment of obesity, sarcopenia,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090247570 - Pharmaceuticals: The present invention relates to the use of a CCR5 antagonist in an HIV infected patient to enhance their immune reconstitution and so treat to HIV related opportunistic conditions resulting from the immunocompromised state of the HIV patient. The invention also allows treatment with a CCR5 antagonist of patients having... Agent: Pfizer Inc Mary J Hosley

20090247573 - (hetero)aryl cyclohexane derivatives: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247574 - 3-amino-pyridine derivatives for the treatment of metabolic disorders: e

20090247572 - Agent for treating atrial fibrillation: It is intended to provide an agent for treating atrial fibrillation, comprising an If current inhibitor as an active ingredient. In the present invention, the means for resolution comprises an agent for treating atrial fibrillation, comprising an If current inhibitor as an active ingredient. In particular, it comprises an agent... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090247575 - Stabilizing lipid compositions for oral pharmaceutical agents: The present invention relates to a pharmaceutical composition for oral administration comprising an exceptionally labile active agent, a stabilizing vehicle comprising liquid triglycerides and a desiccant, wherein the composition is storage stable for an extended period without substantial degradation of the active agent.... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20090247578 - 5-hydroxymethyl-oxazolidin-2-one-derivatives and their uses as antibacterials: e

20090247576 - Anti-tumor agent for multiple myeloma: The object of the invention is to provide a pharmaceutical composition and a therapeutic method which can exert their effects with higher efficiency on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR3, a cell that has a t(4;14) translocation and... Agent: Darby & Darby P.c.

20090247577 - Pyrrolidine derivatives useful as bace inhibitors: e

20090247579 - 2-[3h-thiazol-2-ylidinemethyl]pyridines and related compounds and their use:

20090247580 - Nitroxide radioprotector formulations and methods of use: Pharmaceutical compositions useful in preventing and treating negative side effects accompanying radiotherapy are disclosed. More particularly, new formulations that can be applied to the skin and mucous membranes of patients undergoing radiotherapy and methods of using these formulations are disclosed.... Agent: Knobbe Martens Olson & Bear LLP

20090247581 - Organic compounds: The present invention relates to a process for the synthesis of (S)-2′[2-1-(methyl-2-piperidyl) ethyl] cinnamanilide (I) or salts or pharmaceutically acceptable prodrugs thereof:... Agent: Novartis Corporate Intellectual Property

20090247582 - Methods of treating atherosclerosis: e

20090247583 - Pharmaceutical composition comprising, in combination, saredutant and paroxetine: A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from trans-(−)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine and pharmaceutically acceptable salts thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090247584 - Phenoxy-piperidines for the treatment of diseases such as schizophrenia and depression: Compounds of the formula (I), in which R1, R2′, R2″, R2′″, R3 and n are as defined in Claim 1, are effectors of the nicotinic and/or muscarinic acetylcholine receptor and are suitable for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases,... Agent: Millen, White, Zelano & Branigan, P.c.

20090247585 - Pharmaceutical composition comprising, in combination, saredutant and escitalopram: A subject-matter of the present invention is pharmaceutical compositions comprising, in combination, at least one active ingredient chosen from (S)-(−)-N-[4-(4-acetamido-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)butyl]-N-methylbenzamide and pharmaceutically acceptable salts thereof and at least one second active ingredient chosen from (S)-(+)-1-[4-(3-(dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile and pharmaceutically acceptable salts thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090247587 - 1,3-dihydroisobenzofuran derivatives: The object is to provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090247586 - Carboxamides for controlling micro-organisms in plant and material protection: e

20090247588 - 2-trifluoromethylnicotinamide derivatives as hdl-cholesterol raising agents:

20090247589 - Monocarboxylates for modifying macrophage function: The present invention is directed to methods of inhibiting the production of proinflammatory agents by macrophages by contacting the cells with a monocarboxylate such as nicotinic acid. The invention also includes methods of treating diseases that are associated with macrophage activation such as atherosclerosis; systemic lupus erythematosus; rheumatoid arthritis; inflammatory... Agent: Law Office Of Michael A. Sanzo, Llc

20090247590 - Indane amides: The invention relates to novel compounds and processes for their preparation and their use for preparing medicaments for the treatment of disorders, especially hyper-proliferative disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090247591 - Substituted cyclohexyldiamines: The invention relates to compounds that have an affinity to the μ-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain or other conditions.... Agent: Norris, Mclaughlin & Marcus, Pa

20090247592 - Epothilones c, d, e, and f, preparation and compositions: The present invention relates to epothilones C, D, E, and F, their preparation and their use for the production of therapeutic compositions and compositions for plant protection.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090247593 - N-thiazol-2-yl-benzamide derivatives: e

20090247594 - Therapeutic compounds:

20090247595 - Process for the preparation of tetrazolyl compounds: The invention provides a method for preparing candesartan cilexetil and related tetrazolyl compounds. More particularly, the invention relates to the preparation of candesartan cilexetil and related tetrazolyl compounds and includes a method of removing a protective group (e.g., triphenylmethane (trityl) protecting group) from an N-protected tetrazolyl compound using a Lewis... Agent: Frommer Lawrence & Haug

20090247596 - Thiophenecarboxamide derivatives as ep4 receptor ligands: The invention is directed to thiophenecarboxamide derivatives of formulae I and II as EP4 receptor ligands, antagonists or agonists, useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, osteoarthritis, rheumatoid arthritis, cancer and glaucoma. Pharmaceutical compositions and methods of use are also included.... Agent: Merck And Co., Inc

20090247597 - Agrochemical formulations that can be dispersed in water containing polyalkoxytriglycerided as penetration enhances: The present invention relates to novel water-dispersible agrochemical formulations such as, for example, water-based suspension concentrates and water-dispersible granules of agrochemically active compounds comprising a penetrant from the class of the polyalkoxytriglycerides, to a process for preparing these formulations and to their use for applying the active compounds comprised therein.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, Pc

20090247599 - Methods of treating cell proliferative disorders using a compressed temozolomide dosing schedule: There are disclosed methods and kits for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing schedules.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090247598 - Treatment methods: There are disclosed methods for treating cancer in a patient in need of such treating comprising administering temozolomide according to improved dosing regimen and/or schedules based on the patient's MGMT level. Additional improved methods for treating patients with temozolomide are also disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090247600 - Remedy for corneal diseases: A therapeutic agent for a corneal disease comprising ozagrel or a salt thereof as an active ingredient is provided. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090247601 - Peptide derivatives with therapeutic activity: Dipeptide compounds containing a histidine residue proved to have interesting blocking activity on secondary products from lipid oxidative stress, in particular on unsaturated aldehydes such as malondialdehyde and hydroxynonenal, which are known to contribute to the inset of quite a number of chronic pathologies such as neurodegenerative, inflammatory chronic, cardiovascular... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.a.

20090247602 - Cosmetic use of conjugated compounds of indolic auxins: p

20090247603 - Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor: The present invention is a new stable drug composition particularly suitable for use as an antihypercholesterolaemic or antihyperlipidaemic agent. The present invention is specifically a drug composition comprising a pharmaceutical, a complexing agent and a surfactant, and a method for manufacturing same. When applied to unstable drugs with low solubility... Agent: Peacock Myers, P.c.

20090247616 - Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety: The present invention is a method for the treatment of anxiety and related disorders comprising administering to a subject in need thereof a therapeutically effective amount of one or more novel benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as herein defined. The present invention is directed to... Agent: Philip S. Johnson Johnson & Johnson

20090247618 - Process for preparation of benzo-fused heteroaryl derivatives: The present invention is directed to processes for the preparation of benzo-fused heteroaryl derivatives, useful for the treatment of epilepsy and related disorders. The present invention is further directed to processes for the preparation of intermediates in the synthesis of the benzo-fused heteroaryl derivatives.... Agent: Philip S. Johnson Johnson & Johnson

20090247617 - Process for the preparation of benzo-fused heteroaryl sulfamates: The present invention is directed to a process for the preparation of benzo-fused heteroaryl sulfamates, useful for the treatment of epilepsy and related disorders.... Agent: Philip S. Johnson Johnson & Johnson

20090247619 - Cannabinoid-containing compositions and methods for their use: This invention relates to cannabinoid-containing compositions, particularly cannabinoid-containing gel formulations and methods for the treatment of traumatic injury, e.g., strains, sprains and contusions, and disease conditions, e.g., arthritis, particularly osteoarthritis. The methods involve topically applying a cannabinoid or a cannabinoid-containing composition to a subject's skin near, or distant from, the... Agent: Crowell & Moring LLP Intellectual Property Group

20090247620 - Benzochromene derivatives for use in liquid crystal media and as therapeutic active substances: where the various parameters have the meaning indicated in the text, and to liquid-crystal media which comprise these compounds, and to the use of the media in electro-optical displays, in particular in TN, OCB, LCOS and/or IPS-LCDs, and to the use of the compounds and physiologically acceptable derivatives thereof as... Agent: Millen, White, Zelano & Branigan, P.c.

20090247621 - Diosmetin compounds, a process for their preparation and pharmaceutical composition containing them: e

20090247622 - Natural topical compositions for the prevention and treatment of diaper rashes and related conditions: The treatment and prevention of skin irritations, including diaper rash, is facilitated with the topical application of cranberry anthocyanins in a cosmetically acceptable vehicle.... Agent: Abelman, Frayne & Schwab

20090247623 - Derivatives of epirubicin, their medicinal application and pharmaceuticaly acceptable forms of drugs: The present invention relates to novel derivatives of epirubicin, pharmaceutical composition comprising these derivatives, and uses of epirubicin and its derivative for treating HCV.... Agent: Brooks Kushman P.c.

20090247624 - Formulations of radioprotective alpha beta unsaturated aryl sulfones: Solution and suspension formulations are provided for administration prior to or after exposure to ionizing radiation for reducing toxic effects of the radiation in a subject which comprises an effective amount of at least one radioprotective α,β unsaturated aryl sulfone wherein the composition has a pH within the range of... Agent: Law Offices Of Khalilian Sira, Llc

20090247625 - Compositions containing lignan-class compounds: An object of the invention is to provide compositions containing lignan-class compounds as dissolved at high concentrations. The compositions having lignan-class compounds such as sesamin and episesamin dissolved in solvent oils or fats that contain triglycerides of middle-chain fatty acids having 8-12 carbon atoms, preferably triglycerides of caprylic acid and/or... Agent: Drinker Biddle & Reath (dc)

20090247626 - Method of treating dyslipidemia using naturally occurring diterpene: A method for treatment and or/prevention of dyslipidemia is provided. The invention relates to reducing low density lipoprotein cholesterol concentration by using naturally occurring diterpene (16α-hydroxycleroda-3,13(14)Z-dien-15,16-olide, a compound having formula (1)) isolated from leaves of Polyalthia longifolia.... Agent: Greenlee Winner And Sullivan P C

20090247627 - Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists: wherein R1, R2, R3, R4, R5, R6, R7, and n are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor... Agent: Theravance, Inc.

20090247628 - Substituted phenylcyclohexylglycolates: Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20090247629 - Dimer poly-quaternary ester compounds: The present invention relates to a novel class of polymeric compounds having specific quaternized amine based upon a dimer acid reacted with an alkanolamine to make an ester quaternary compound. Dimer acid is a C-36 diacid having a cyclic structure and two amine groups that allow for the synthesis of... Agent: Kevin O'lenick

20090247632 - Dermatological compositions and methods: Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.... Agent: Mueting, Raasch & Gebhardt, P.a.

20090247630 - Dermatological compositions comprising at least one naphthoic acid compound and at least one film-forming agent and treatment of keratinization disorders therewith: Topically applicable, reduced-irritant dermatological/cosmetic compositions useful for the prevention/treatment of a variety of keratinization disorders, for example acne vulgaris, contain at least one naphthoic acid compound essentially uniformly distributed therethrough and an amount of at least one hydrophilic film-forming agent, formulated into topically applicable, physiologically acceptable media therefor.... Agent: Buchanan, Ingersoll & Rooney Pc

20090247631 - Enzymatic production of peracids using perhydrolytic enzymes: A process is provided to produce a concentrated aqueous peracid solution in situ using at least one enzyme having perhydrolase activity in the presence of hydrogen peroxide (at a concentration of at least 500 mM) under neutral to acidic reaction conditions from suitable carboxylic acid esters (including glycerides) and/or amides... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20090247634 - Methods for identifying modulators of eoxin formation: p

20090247633 - Nutrient extracts derived from green plant materials: An extract from green plant materials includes controlled concentrations of nutritional components. In one embodiment, the nutritional components include at least one xanthophyll, at least one hydrocarbon carotene, and at least one fatty acid wherein the xanthophyll, hydrocarbon carotene, and fatty acid each have about equal weight percentages. In a... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090247636 - Agent for suppression of gastric emptying comprising 4-hydroxyisoleucine: The present invention aims to provide a more effective gastric emptying suppressant and food intake suppressant, wherein the solving means are a gastric emptying suppressant containing 4-hydroxyisoleucine or a salt thereof and a food intake suppressant containing 4-hydroxyisoleucine or a salt thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090247635 - Method for treating anal pruritis and other perianal disorders: The invention relates to methods and compositions for the treatment of pruritis ani and other perianal disorders. There are currently few treatments for these conditions, many of which have significant side effects. The methods of the invention involve the administration, in a cream or lotion of pregabalin, an anti-epileptic agent... Agent: Jonathan D. Feuchtwang

20090247637 - Novel anthranilic acid derivatives: e

20090247638 - Pharmaceutical use of cox-2-inhibitors in angiogenesis-mediated ocular disorders:

20090247639 - Sulfonic acid and aldehyde condensation polymers for the treatment and prevention of hpv: The present invention relates to a method of treating and preventing a papillomavirus infection in an individual, comprising administering to the individual a therapeutically effective amount of a condensation polymer of an aromatic sulfonic acid and an aldehyde, or a pharmaceutically acceptable salt thereof.... Agent: Foley And Lardner LLP Suite 500

20090247640 - Antimicrobials having polyquaternary ammoniums and alcohol-bearing amidoamines and methods for their use: Antimicrobial or preservative compositions with high user comfort and/or low ocular irritation. The compositions comprise a polyquaternary ammonium compound and an amidoamine having an alcohol group and exhibit synergistic antimicrobial activity. The compositions may be used as stand-alone antimicrobials/preservatives or may be incorporated into other ocular compositions such as those... Agent: Abbott Medical Optics, Inc.

20090247641 - Hydrazone agents to treat cutaneous lesions: A method is disclosed for treating hyperproliferative body surface lesions, including cancerous or precancerous lesion, such as warts or anogenital cancers, by applying a polyaryl mononitro- or dinitrophenylhydrazone such as (I) wherein R1 is hydrogen, hydroxy, 2- or 4-hydroxyphenyl, acetate, nitroso, phosphate, azido, nitrile, amino, dimethylamino, sulfate, methylsulfonate, phosphate, succinate... Agent: Dickstein Shapiro LLP

20090247642 - Synthesis and preparations of metoprolol and its salts: The invention relates to an improved process for preparing metoprolol and its salts.... Agent: Hogan & Hartson LLP Ip Group, Columbia Square

20090247643 - Medicinal herbal composition for treating infection: Herbal compositions derived from Kenyan plants are provided for the treatment of HIV and other infectious diseases. The herbal compositions can include the extracts of up to 14 plants, including the root of Dovyalis abyssinica and Clutia robusta. Also provided are methods for extracting alkaloids and other compounds from the... Agent: Cooper & Dunham, LLP

20090247644 - Memantine formulations: The present invention relates to pharmaceutical compositions prepared from equant-shaped crystals of memantine, such as orally dissolving formulations, e.g., tablets (ODTs) and films (ODFs), and to methods of treating conditions, including childhood behavioral disorders (e.g., autism) and Alzheimer's disease by administering the same.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20090247645 - Stabilized compositions of alkylating agents and methods of using same: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum... Agent: Gfd Patents, Llc

20090247646 - Use of resveratrol and derivatives thereof for promoting the wellness state in mammals: The invention relates to the use of resveratrol, a derivative, metabolite or analogue thereof for promoting the wellness state of a mammal or for changing gene expression profiles in older adult mammals towards conformity with expression profiles found in younger adult mammals as well as to their use for the... Agent: Nixon & Vanderhye, Pc

20090247647 - Method of stimulating proteoglycan synthesis in cells: A method of stimulating the production of proteoglycans in a living animal cell comprising administering one or more Vitamin D3 metabolites to the living cells is provided.... Agent: Nelson Mullins Riley & Scarborough, LLP

20090247648 - Sebum absorption compositions: Sebum absorption compositions are disclosed which include (a) 1% to 20% by weight of the composition of a sebum absorption ingredient; and (b) 20% to 99% by weight of the composition of a volatile solvent.... Agent: Fulbright & Jaworski L.l.p.

20090247649 - Compositions using evaporable silicone carriers for cosmetics, cleaning and care product compositions: where R1 and R2 are selected from the group of linear or branched monovalent hydrocarbon radicals having from one to eight carbon atoms and where each R3, R4, R5, R6, and R7 is independently selected from the group of monovalent hydrocarbon radicals having from one to sixty carbon atoms; and... Agent: Dilworth & Barrese, LLP

20090247650 - Novel cationic associative polyurethanes and their use as thickeners: e

20090247651 - Bioadhesive composition formed using click chemistry: The present disclosure provides compositions which may be utilized as adhesives or sealants in medical and surgical applications. The compositions may, in embodiments, be formed from the cycloaddition reaction of a first component possessing at least one azide group with a second component possessing at least one alkyne group.... Agent: Tyco Healthcare Group Lp

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140410: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 2.65091 seconds

PATENT INFO